<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">30766</article-id><article-id pub-id-type="doi">10.7554/eLife.30766</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Dnmt3a is an epigenetic mediator of adipose insulin resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-94516"><name><surname>You</surname><given-names>Dongjoo</given-names></name><email>dongjoo@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94517"><name><surname>Nilsson</surname><given-names>Emma</given-names></name><email>emma_a.nilsson@med.lu.se</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94518"><name><surname>Tenen</surname><given-names>Danielle E</given-names></name><email>detenen@bidmc.harvard.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94828"><name><surname>Lyubetskaya</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94520"><name><surname>Lo</surname><given-names>James C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94521"><name><surname>Jiang</surname><given-names>Rencong</given-names></name><email>dhzhang@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94522"><name><surname>Deng</surname><given-names>Jasmine</given-names></name><email>jasminedeng@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94649"><name><surname>Dawes</surname><given-names>Brian A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99671"><name><surname>Vaag</surname><given-names>Allan</given-names></name><email>allan.vaag@astrazeneca.com</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94525"><name><surname>Ling</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-7822"><name><surname>Rosen</surname><given-names>Evan D</given-names></name><email>erosen@bidmc.harvard.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-93722"><name><surname>Kang</surname><given-names>Sona</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9831-677X</contrib-id><email>kangs@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Nutritional Sciences and Toxicology Department</institution><institution>University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Epigenetics and Diabetes Unit, Department of Clinical Sciences</institution><institution>Lund University Diabetes Centre, Scania University Hospital</institution><addr-line><named-content content-type="city">Malmö</named-content></addr-line><country>Sweden</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Division of Endocrinology, Diabetes and Metabolism</institution><institution>Beth Israel Deaconess Medical Center</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Broad Institute of Harvard and MIT</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Weill Cornell Medical College</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Diabetes and Metabolism, Department of Endocrinology</institution><institution>Rigshospitalet, University of Copenhagen</institution><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Early Clinical Development</institution><institution>AstraZeneca, Innovative Medicines</institution><addr-line><named-content content-type="city">Göteborg</named-content></addr-line><country>Sweden</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-48282"><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><role>Reviewing Editor</role><aff><institution>Maine Medical Center Research Institute</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e30766</elocation-id><history><date date-type="received" iso-8601-date="2017-07-26"><day>26</day><month>07</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-10-29"><day>29</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, You et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>You et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-30766-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary" xlink:href="10.7554/eLife.33298"/><related-object ext-link-type="url" xlink:href="https://elifesciences.org/articles/e30766v1"><date date-type="v1" iso-8601-date="2017-11-01"><day>01</day><month>11</month><year>2017</year></date></related-object><abstract><object-id pub-id-type="doi">10.7554/eLife.30766.001</object-id><p>Insulin resistance results from an intricate interaction between genetic make-up and environment, and thus may be orchestrated by epigenetic mechanisms like DNA methylation. Here, we demonstrate that DNA methyltransferase 3a (Dnmt3a) is both necessary and sufficient to mediate insulin resistance in cultured mouse and human adipocytes. Furthermore, adipose-specific Dnmt3a knock-out mice are protected from diet-induced insulin resistance and glucose intolerance without accompanying changes in adiposity. Unbiased gene profiling studies revealed <italic>Fgf21</italic> as a key negatively regulated Dnmt3a target gene in adipocytes with concordant changes in DNA methylation at the <italic>Fgf21</italic> promoter region. Consistent with this, Fgf21 can rescue Dnmt3a-mediated insulin resistance, and DNA methylation at the <italic>FGF21</italic> locus was elevated in human subjects with diabetes and correlated negatively with expression of <italic>FGF21</italic> in human adipose tissue. Taken together, our data demonstrate that adipose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>adipocyte</kwd><kwd>insulin resistance</kwd><kwd>epigenetic</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>102173</award-id><principal-award-recipient><name><surname>Rosen</surname><given-names>Evan D</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>102170</award-id><principal-award-recipient><name><surname>Rosen</surname><given-names>Evan D</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>085171</award-id><principal-award-recipient><name><surname>Rosen</surname><given-names>Evan D</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>15SDG25240017</award-id><principal-award-recipient><name><surname>Kang</surname><given-names>Sona</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>116008</award-id><principal-award-recipient><name><surname>Kang</surname><given-names>Sona</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mouse and tissue culture studies reveal that adipose DNA methyltransferase 3a mediates insulin resistance, partially through repressing the expression of <italic>FGF21</italic>.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Insulin resistance (IR) is generally defined as a reduced ability of insulin to provoke metabolic responses, such as glucose uptake. Several mechanistic drivers of IR have been proposed, including defects in the insulin signal transduction pathway, dysfunctional mitochondrial respiration, and ER stress (<xref ref-type="bibr" rid="bib8">Boucher et al., 2014</xref>; <xref ref-type="bibr" rid="bib29">Gregor and Hotamisligil, 2011</xref>; <xref ref-type="bibr" rid="bib31">Houstis et al., 2006</xref>; <xref ref-type="bibr" rid="bib63">Ozcan et al., 2004</xref>; <xref ref-type="bibr" rid="bib70">Samuel and Shulman, 2012</xref>). The data supporting the involvement of these non-mutually exclusive pathways are convincing, but additional mechanisms are also likely to participate in the development of IR. Nuclear pathways in particular (i.e. transcriptional and epigenomic mechanisms) are likely to play an important role, given that IR often develops over a time course that is inconsistent with rapid signal transduction events (<xref ref-type="bibr" rid="bib38">Kang et al., 2015</xref>; <xref ref-type="bibr" rid="bib77">Tan et al., 2015</xref>). Furthermore, there is a large body of data from humans and rodents indicating that the propensity for IR can be passed transgenerationally; such ‘fetal programming’ studies strongly imply an epigenetic basis for IR (<xref ref-type="bibr" rid="bib10">Carone et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Heijmans et al., 2008</xref>; <xref ref-type="bibr" rid="bib46">Li et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Tobi et al., 2014</xref>). Finally, thiazolidinedione drugs, which activate the transcription factor PPARγ, provide one of the only pharmacological therapies for IR (<xref ref-type="bibr" rid="bib73">Soccio et al., 2014</xref>; <xref ref-type="bibr" rid="bib74">Step et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">Sugii et al., 2009</xref>). Taken together, these data strongly suggest that epigenomic and transcriptional mechanisms must be in play in the etiopathogenesis of IR (<xref ref-type="bibr" rid="bib39">Kang et al., 2016</xref>).</p><p>DNA methylation is a reversible epigenetic mark involving the covalent transfer of a methyl group to the C-5 position of a cytosine residue, usually in the context of a CpG doublet, by DNA methyltransferases (Dnmts) (<xref ref-type="bibr" rid="bib66">Robertson, 2005</xref>). Long thought to be a static epigenetic mark, emerging evidence suggests that methylated DNA undergoes dynamic and reversible remodeling in somatic cells during developmental, physiological, and pathogenic pathophysiological processes (<xref ref-type="bibr" rid="bib3">Barres et al., 2013</xref>; <xref ref-type="bibr" rid="bib4">2009</xref>; <xref ref-type="bibr" rid="bib6">Benner et al., 2015</xref>; <xref ref-type="bibr" rid="bib42">Kirchner et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Multhaup et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Siersbæk et al., 2017</xref>). As an example, a bout of intense exercise can induce DNA hypomethylation at the <italic>PPARGC1a</italic> locus in human skeletal muscle within hours, followed by increased gene expression; these effects were reversed after resting (<xref ref-type="bibr" rid="bib5">Barrès et al., 2012</xref>). Mounting evidence points to a role for DNA methylation in the pathogenesis of metabolic disorders. For example, the obesity-prone <italic>agouti</italic> mouse has reduced DNA methylation at the regulatory region for the <italic>Agouti</italic> gene, leading to enhanced expression and subsequent inhibition of the satiety-inducing MC4 receptor (<xref ref-type="bibr" rid="bib86">Xie et al., 2013</xref>). Multiple studies have shown that changes in DNA methylation at key metabolic genes, such as <italic>Cox7a1</italic> (<xref ref-type="bibr" rid="bib68">Rönn et al., 2008</xref>)<italic>, IGF-2</italic> (<xref ref-type="bibr" rid="bib30">Heijmans et al., 2008</xref>), and <italic>Pomc</italic> (<xref ref-type="bibr" rid="bib21">Ehrlich et al., 2010</xref>), associate with various metabolic insults including aging, obesity, anorexia, and prenatal exposure to famine. Moreover, recent genome-wide profiling studies have identified distinct global DNA methylation patterns that associate with obesity and diabetes in humans (<xref ref-type="bibr" rid="bib17">Dayeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Feinberg et al., 2010</xref>; <xref ref-type="bibr" rid="bib42">Kirchner et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Multhaup et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Nilsson et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Volkmar et al., 2012</xref>; <xref ref-type="bibr" rid="bib83">Volkov et al., 2017</xref>). Altered DNA methylation is linked to the transgenerational passage of metabolic disorders (<xref ref-type="bibr" rid="bib56">Ng et al., 2010</xref>; <xref ref-type="bibr" rid="bib85">Wei et al., 2014</xref>). Despite numerous studies showing a link between DNA methylation and metabolic dysregulation, the cause-and-effect relationship between the two remains largely unknown.</p><p>In mammals, five Dnmt family members have been identified: <italic>Dnmt1</italic>, <italic>Dnmt2</italic> (also known as <italic>Trdmt1</italic>), <italic>Dnmt3a</italic>, <italic>Dnmt3b</italic> and <italic>Dnmt3l</italic>, yet only three (<italic>Dnmt1</italic>, <italic>3a</italic>, and <italic>3b</italic>) possess DNA methyltransferase activity (<xref ref-type="bibr" rid="bib66">Robertson, 2005</xref>). Dnmt1 (the maintenance DNA methyltransferase) has a preference to methylate hemimethylated DNA whereas Dnmt3a and 3b prefer unmethylated DNA as substrate, and thus act as de novo DNA methyltransferases (<xref ref-type="bibr" rid="bib66">Robertson, 2005</xref>). Dnmt3l is homologous to the other Dnmt3s but lacks catalytic activity (<xref ref-type="bibr" rid="bib66">Robertson, 2005</xref>) and <italic>Dnmt2</italic> has sequence homology to all Dnmts but methylates cytoplasmic tRNA, and not DNA (<xref ref-type="bibr" rid="bib66">Robertson, 2005</xref>). Administration of a small molecule Dnmt inhibitor has been shown to improve insulin sensitivity in the setting of obesity, in part by demethylating the <italic>Adipoq</italic> promoter, and a role for Dnmt1 in this process was suggested by genetic knockdown studies in cultured adipocytes (<xref ref-type="bibr" rid="bib41">Kim et al., 2015</xref>).</p><p>Here, we identify Dnmt3a as a key epigenetic determinant of obesity-associated IR in adipose tissue. Dnmt3a plays a causal role in the development of cell autonomous IR in mouse and human adipocytes in a manner that is dependent on its catalytic activity. Consistent with results from adipocytes in vitro, we find that adipose-specific Dnmt3a deficiency in vivo confers protection from diet-induced IR and glucose tolerance without accompanying changes in body weight or adiposity. In addition, unbiased gene expression profiling suggests that Dnmt3a acts as primarily as a gene repressor, and reveals a set of adipocyte-specific target genes, including <italic>Fgf21</italic>. Further, we demonstrate that Dnmt3a mediates IR, at least in part, by methylating specific <italic>cis</italic>-regulatory elements in the <italic>Fgf21</italic> gene and thus suppressing its expression. We also provide evidence that similar mechanisms might be at play in human adipose tissue. These studies identify Dnmt3a as a novel epigenetic mediator of IR in adipocytes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Adipose expression of Dnmts inversely correlates with insulin sensitivity</title><p>To identify a potential role for Dnmts in the pathogenesis of insulin resistance, we compared their expression levels in insulin-sensitive metabolic tissues (i.e. liver, muscle, and adipose depots) in various metabolic settings. In a diet-induced obesity (DIO) mouse model, <italic>Dnmt1</italic> and <italic>Dnmt3a</italic> mRNA expression was elevated in adipose tissue, especially in epididymal and mesenteric WAT (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Dnmt3a expression was significantly induced by HFD in skeletal muscle, but to a lesser degree than in adipose tissue. No effect of HFD was observed in liver (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–C</xref>). In genetically obese <italic>ob/ob</italic> mice, mRNA expression of all three functional <italic>Dnmts</italic> was elevated in adipose tissue (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Importantly, expression of these genes was significantly reduced after treatment with the insulin sensitizer rosiglitazone (Rosi) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Increased adipose expression of Dnmt3a was confirmed by immunoblotting in DIO mice (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>). Relative expression of Dnmt3a was higher in eWAT compared to skeletal muscle and liver compared in normal chow-fed mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D–E</xref>). <italic>Dnmt2</italic> and <italic>Dnmt3l</italic> mRNA displayed minimal expression in adipose tissue (not shown). Together, this led us to hypothesize that Dnmts may have a direct functional role in the pathogenesis of adipose IR.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.002</object-id><label>Figure 1.</label><caption><title>Increased adipose expression of Dnmts in obesity.</title><p>(<bold>A</bold>) <italic>Dnmt</italic> mRNA expression in adipose from chow- and high fat-fed (HFD) C57Bl/6 mice (<bold>A</bold>); <italic>n</italic> = 6 mice, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.) and (<bold>B</bold>) in adipose tissue from <italic>ob/</italic>+and <italic>ob/ob</italic> mice in the presence and absence of ​rosiglitazone treatment (right; <italic>n</italic> = 7 for <italic>ob/</italic>+, <italic>n</italic> = 8 for <italic>ob/</italic>+plus Rosi, <italic>n</italic> = 7 for <italic>ob/ob</italic> with and without Rosi, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>C</bold>) Western blot showing Dnmt3a protein levels in adipose tissue from chow vs. HFD mice. (<bold>D</bold>) Quantification of western blot in (<bold>C</bold>).</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.005</object-id><label>Figure 1—source data 1.</label><caption><title>Figure 1—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Expression of Dnmts in various metabolic tissues.</title><p>(<bold>A</bold>) <italic>Dnmt</italic> mRNA expression in inguinal WAT (iWAT, <italic>n</italic> = 6), BAT (<italic>n</italic> = 6), and mesenteric WAT (mesWAT, <italic>n</italic> = 5) from chow- and high fat-fed C57Bl/6 mice (p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>B, C</bold>) <italic>Dnmt</italic> mRNA expression in liver and skeletal muscle from chow- and high fat-fed C57Bl/6 mice (liver: <italic>n</italic> = 6, 5, skeletal muscle: <italic>n</italic> = 6, six mice, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>D</bold>) Dnmt3a protein expression in eWAT, liver, and skeletal muscle in chow-fed C57Bl/6 mice (<bold>E</bold>) Quantification of western blot in <bold>D</bold> (<italic>n</italic> = 3, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.) (<bold>F</bold>) Dnmt3a protein expression of various adipose depots in chow-fed C57Bl/6 mice. (<bold>G</bold>) Quantification of western blot in (<bold>F</bold>) (<italic>n</italic> = 3, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig1s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.004</object-id><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Figure 1—figure supplement 1—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig1-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-2"><title>Knock-down of Dnmt3a confers protection from drug-mediated IR</title><p>Given the inverse correlation of adipose <italic>Dnmt</italic> expression with insulin sensitivity, we sought to test the cell autonomous role of Dnmts in the development of IR. To that end, individual Dnmts were knocked-down in mature 3T3-L1 adipocytes using two distinct short hairpin RNAs (shRNAs) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–F</xref>). To promote IR, cells were treated with dexamethasone (Dex) and TNF-α (TNF) (<xref ref-type="bibr" rid="bib31">Houstis et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">Kang et al., 2015</xref>) for an additional four days. Knock-down of individual Dnmts did not have a major impact on the basal level of insulin sensitivity when assessed by insulin-stimulated glucose uptake (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–E</xref>). However, knock-down of <italic>Dnmt3a</italic>, but not <italic>Dnmt1</italic> or <italic>Dnmt3b</italic>, protected adipocytes from Dex- and TNF-mediated IR as assessed by insulin-stimulated glucose uptake and signal transduction (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–E</xref>). Given the elevated expression of adipose Dnmts in obesity, we were prompted to test whether overexpression of Dnmts per se is sufficient to drive IR in adipocytes. Individual Dnmts were expressed in mature 3T3-L1 adipocytes by lentiviral delivery. Interestingly, overexpression of Dnmt3a and 3b, but not Dnmt1, potently inhibited insulin-stimulated glucose uptake (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Additionally, we tested whether the causal role of Dnmt3a in the development of insulin resistance is conserved in human adipocytes. Overexpression of Dnmt3a powerfully inhibited insulin-stimulated glucose uptake in in vitro differentiated adipocytes from human adipose derived stem cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Together, our gain- and loss-of-function studies in vitro show that Dnmt3a is both necessary and sufficient to mediate IR in adipocytes in a cell autonomous manner.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.006</object-id><label>Figure 2.</label><caption><title>Dnmt3a is sufficient and necessary to mediate cell autonomous IR in vitro.</title><p>(<bold>A</bold>) Two independent hairpins against ​Dnmt3a (versus scrambled control shRNA; shScr) were delivered to mature 3T3-L1 adipocytes (Day 8) via lentiviral transduction. Cells were then treated with ​Dex and ​TNF for 4 days and assessed for insulin-stimulated ​glucose uptake (<sup>3</sup>H-2-DG assay, n = 6, p&lt;0.05). Shown is the % of insulin-stimulated glucose uptake rescued by <italic>Dnmt3a</italic> knockdown (n = 6, p&lt;0.05). (<bold>B</bold>) Cells in (<bold>A</bold>) with #2 shDnmt3a hairpin and control cells were withdrawn from serum for 6 hr, stimulated with 20 nM insulin for 5 min and subjected to immunoblotting with antibodies against total and phospho-AKT and –IRS-1 with and without insulin. (<bold>C</bold>) Basal and insulin-stimulated glucose uptake in mature 3T3-L1 and (<bold>D</bold>) in in vitro-differentiated primary human adipocytes transduced with lentivirus expressing Dnmts or the empty plasmid vector, pCDH (<italic>n</italic> = 6, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.011</object-id><label>Figure 2—source data 1.</label><caption><title>Figure 2—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Knock-down efficiency of Dnmt hairpins.</title><p>(<bold>A-C</bold>) Two independent hairpins against ​Dnmt1, 3a, and 3b (versus scrambled shRNA; shScr) were delivered to mature 3T3-L1 adipocytes (Day 8) via lentiviral transduction. Shown is mRNA (<italic>n</italic> = 3, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>D–F</bold>) The Flag-tagged version of expression vectors for Dnmt1, 3a, and 3b were co-transfected with hairpins against them in 293 T cells. After 2 days of transfection, Flag western was performed.</p><p><supplementary-material id="fig2s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.008</object-id><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Figure 2—figure supplement 1—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.009</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Dnmt3a is necessary for Dex- and TNF-mediated IR.</title><p>(<bold>A–E</bold>) Two independent hairpins against ​Dnmt1, Dnmt3a, and Dnmt3b (versus scrambled shRNA; shScr) were delivered to mature 3T3-L1 adipocytes (Day 8) via lentiviral transduction, and cells were then treated with ​Dex and ​TNF for 4 days and assessed for insulin-stimulated ​glucose uptake (<sup>3</sup>H-2-DG assay, n = 6, p&lt;0.05). Basal and insulin-stimulated glucose uptake shown in (<bold>A, C</bold> and <bold>E</bold>). (<bold>B</bold> and <bold>D</bold>) show the % of insulin-stimulated glucose uptake rescued by <italic>Dnmt1, 3a,</italic> and <italic>3b</italic> knockdown (n = 6, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig2s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.010</object-id><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Figure 2—figure supplement 2—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig2-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig2-figsupp2-v2"/></fig></fig-group></sec><sec id="s2-3"><title>DNA methyltransferase activity is critical for Dnmt3a to mediate IR</title><p>Studies have shown that Dnmt3a can act as a gene repressor using both catalytic-dependent and independent mechanisms (<xref ref-type="bibr" rid="bib2">Bachman et al., 2001</xref>; <xref ref-type="bibr" rid="bib26">Fuks et al., 2001</xref>). Thus, we sought to determine whether DNA methyltransferase activity is required to mediate IR. We initially pursued a pharmacological approach, using two synthetic Dnmt inhibitors, 5-azacytidine (5-Aza) (<xref ref-type="bibr" rid="bib75">Stresemann and Lyko, 2008</xref>), a nucleoside analogue serving as a pseudo-substrate for Dnmts, and RG-108 (<xref ref-type="bibr" rid="bib9">Brueckner et al., 2005</xref>), a non-nucleoside-based drug. Remarkably, both Dnmt inhibitors blocked Dex- and TNF-mediated IR (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). In addition to these synthetic inhibitors, the naturally occurring Dnmt inhibitors (<xref ref-type="bibr" rid="bib65">Rajavelu et al., 2011</xref>) epigallocatechin gallate (ECCG) and theaflavin-3,3′-digallate (TF-3) also showed insulin-sensitizing activity in the setting of Dex- and TNF-mediated IR (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–F</xref>). These data suggest that DNA methyltransferase activity is necessary for Dnmt3 to cause IR. To further probe this hypothesis, we overexpressed a catalytically inactive allele of Dnmt3a (C706S) (<xref ref-type="bibr" rid="bib32">Hsieh, 1999</xref>). Unlike the wild-type allele, Dnmt3a C706S was unable to suppress insulin-stimulated glucose uptake (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Together, the pharmacological and genetic evidence indicates that DNA methyltransferase activity is essential for Dnmt3a to mediate IR.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.012</object-id><label>Figure 3.</label><caption><title>DNA methyltransferase activity is critical for Dnmt3a to mediate IR.</title><p>Insulin-stimulated glucose uptake assay was conducted using 3T3-L1 adipocytes treated with Dnmt inhibitors (<bold>A</bold>, 5-Aza; <bold>B</bold>, RG-108) and Dex or TNF for 4 days. Shown is the % of insulin-stimulated glucose uptake rescued by Dnmt inhibitors (n = 6, p&lt;0.05). (<bold>C</bold>) Basal and insulin-stimulated glucose uptake in mature 3T3-L1 adipocytes transduced with wild-type Dnmt3a vs. a catalytically inactive allele (C706S) (<italic>n</italic> = 6, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.015</object-id><label>Figure 3—source data 1.</label><caption><title>Figure 3—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.013</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Dnmt inhibitors confer protection from Dex- and TNF-mediated IR.</title><p>(<bold>A–F</bold>). Insulin-stimulated glucose uptake assay was conducted on 3T3-L1 adipocytes co-treated with Dex or TNF and the Dnmt inhibitors (<bold>A</bold>) RG-108, (<bold>B</bold>) 5-Azacytidine (5-Aza), (<bold>C, D</bold>) theaflavin-3,3’-digallate (TF3), and (<bold>E, F</bold>) epigallocatechin gallate (ECCG) for 4 days. Basal and insulin-stimulated glucose uptake shown in (<bold>A, B, D, and F</bold>). (<bold>C</bold> and <bold>E</bold>) show the % of insulin-stimulated glucose uptake rescued by Dnmt inhibitors (n = 6, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig3s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.014</object-id><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Figure 3—figure supplement 1—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig3-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-4"><title>Adipose-specific Dnmt3a deficiency confers protection from diet-induced insulin resistance and glucose intolerance</title><p>We next sought to determine whether loss of Dnmt3a in adipocytes could confer protection from diet-induced adipose tissue and systemic IR in vivo. To address this, we generated adipose-specific Dnmt3a knock-out mice (<italic>Dnmt3a<sup>AdiKO</sup></italic>) by crossing Dnmt3a floxed mice (<italic>Dnmt3a<sup>f/f</sup></italic>) (<xref ref-type="bibr" rid="bib57">Nguyen et al., 2007</xref>) to adiponectin-Cre mice (<xref ref-type="bibr" rid="bib20">Eguchi et al., 2011</xref>) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>). On chow diet, male WT and <italic>Dnmt3a<sup>AdiKO</sup></italic> animals did not show any obvious change in their body weight, insulin sensitivity, glucose tolerance, or insulin levels (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–D</xref>). On HFD (45% fat), <italic>Dnmt3a<sup>AdiKO</sup></italic> mice still showed no significant differences in body weight or composition relative to littermate controls (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). Moreover, the effect of long-term fasting (16 hr) on body weight or body composition did not differ between genotypes (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), suggesting that gross energy homeostasis is not altered in the knock-out animals. Despite no obvious change in energy balance, high fat fed male <italic>Dnmt3a<sup>AdiKO</sup></italic> mice exhibited improved glucose tolerance (<xref ref-type="fig" rid="fig4">Figure 4D,E</xref>) and insulin sensitivity (<xref ref-type="fig" rid="fig4">Figure 4F,G</xref>) with reduced serum insulin in the fed state (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Consistent with their metabolic improvement, male <italic>Dnmt3a<sup>AdiKO</sup></italic> mice display increased insulin signal transduction in adipose tissue, as demonstrated by increased insulin-stimulated phosphorylation of IRS and AKT (<xref ref-type="fig" rid="fig4">Figure 4I,J</xref>). Similarly, female <italic>Dnmt3a<sup>AdiKO</sup></italic> mice display improved insulin sensitivity and glucose tolerance on HFD without a change in body weight (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A–C</xref>). We next assessed whether insulin sensitization could be due to either enhanced browning or reduced inflammation of WAT. With regard to the former, we found no consistent change in the expression of major thermogenic genes such as <italic>Ucp1</italic> and <italic>Ppargc1a</italic> in either iWAT and BAT (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A,B</xref>). Additionally, gene expression analysis showed a nonsignificant trend toward reduced expression of proinflammatory genes such as <italic>Tnfa</italic> and <italic>Ccl2</italic> (which encodes MCP-1) in the eWAT of <italic>Dnmt3a<sup>AdiKO</sup></italic> mice (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A</xref>). We also saw no obvious change in the density of crown-like structures between WT and KO tissues (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B</xref>). Together, these results demonstrate that adipose-specific deletion of Dnmt3a confers protection from diet-induced IR in a manner that is independent of adiposity, inflammation, or browning of white adipose tissue.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.016</object-id><label>Figure 4.</label><caption><title>Adipose-specific Dnmt3a KO mice display improved whole body insulin sensitivity and glucose tolerance on HFD.</title><p>(<bold>A</bold>) Body weight of <italic>Dnmt3a<sup>AdiKO</sup></italic> and control mice on HFD (n = 7, 9, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>B</bold>) Body composition after 10 weeks of HFD (n = 7, 9). (<bold>C</bold>) Effect of long-term fasting (16 hr) on body weight or body composition by EchoMRI. Shown is % loss after fasting (n = 14, 14, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>D</bold>) Glucose tolerance test after 9 weeks on HFD (n = 7, 9, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>E</bold>) The area under curve (AUC) in (<bold>D</bold>). (<bold>F</bold>) Insulin tolerance test after 11 weeks on HFD (n = 7, 9, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>G</bold>) AUC in (<bold>F</bold>). (<bold>H</bold>) Fed and fasted insulin levels measured by ELISA (n = 7, 9 p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.) (<bold>I</bold>) Immunoblot of total and phospho-AKT and IRS-1 in eWAT after IP insulin. (<bold>J</bold>) Quantification of western blot in (<bold>I</bold>).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.027</object-id><label>Figure 4—source data 1.</label><caption><title>Figure 4—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.017</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Adipose-specific deletion of Dnmt3a.</title><p>Adipose tissue deletion of Dnmt3a was confirmed in 8 wk-old Dn<italic>mt3a<sup>AdiKO</sup></italic> (KO) mice by qPCR (n = 3, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.) (<bold>A</bold>) and western blot (<bold>B</bold>).</p><p><supplementary-material id="fig4s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.018</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Figure 4—figure supplement 1—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig4-figsupp1-v2"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.019</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Metabolic features of <italic>Dnmt3a<sup>AdiKO</sup></italic> mice on chow.</title><p>(<bold>A</bold>) Body weight of <italic>Dnmt3a<sup>AdiKO</sup></italic> mice on chow. Glucose (<bold>B</bold>) and insulin tolerance test (<bold>C</bold>) on 11 and 12 wk old KO and WT mice on chow. (<bold>D</bold>) Insulin levels of fed and fasted chow-fed KO and WT mice as measured by ELISA. (n = 8, 8, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig4s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.020</object-id><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Figure 4—figure supplement 2—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig4-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig4-figsupp2-v2"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.021</object-id><label>Figure 4—figure supplement 3.</label><caption><title>Metabolic features of female <italic>Dnmt3a<sup>AdiKO</sup></italic> on HFD.</title><p>(<bold>A</bold>) Body weight was measured at 8-wk-old mice prior to HFD regimen and at 22-wk-old mice on HFD. Glucose (<bold>B</bold>) and insulin tolerance test (<bold>C</bold>) on 19 and 20 wk old KO and WT mice on HFD. (n = 6, 6, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig4s3sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.022</object-id><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Figure 4—figure supplement 3—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig4-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig4-figsupp3-v2"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.023</object-id><label>Figure 4—figure supplement 4.</label><caption><title>Gene expression profile of thermogenic genes in <italic>Dnmt3a<sup>AdiKO</sup></italic> mice on HFD.</title><p>The expression of major thermogenic genes was measured by qPCR in iWAT (<bold>A</bold>) and BAT (<bold>B</bold>) from WT and KO mice on HFD (iWAT: n = 6,6; BAT n = 5,5 Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig4s4sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.024</object-id><label>Figure 4—figure supplement 4—source data 1.</label><caption><title>Figure 4—figure supplement 4—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig4-figsupp4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig4-figsupp4-v2"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.025</object-id><label>Figure 4—figure supplement 5.</label><caption><title>Gene expression analysis of proinflammatory genes and histology examination of eWAT from <italic>Dnmt3a<sup>f/f</sup> and Dnmt3a<sup>AdiKO</sup></italic> mice on HFD.</title><p>The expression of major proinflammatory genes was measured by qPCR in iWAT (<bold>A</bold>) and BAT (<bold>B</bold>) from WT and KO mice on HFD (iWAT: n = 6, 6; BAT n = 5,5 Student’s <italic>t</italic>-test, mean ±s.e.m.). (<bold>C</bold>) Representative microscopic image of adipose depots from WT and KO mice on HFD after staining with hematoxylin and eosin (H&amp;E).</p><p><supplementary-material id="fig4s5sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.026</object-id><label>Figure 4—figure supplement 5—source data 1.</label><caption><title>Figure 4—figure supplement 5—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig4-figsupp5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig4-figsupp5-v2"/></fig></fig-group></sec><sec id="s2-5"><title>Unbiased gene profiling studies reveal that Fgf21 is a key metabolic target gene of Dnmt3a in adipocytes</title><p>Dnmt3a affects developmental processes by regulating non-overlapping sets of cell type-specific target genes (<xref ref-type="bibr" rid="bib11">Challen et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Nguyen et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Nishikawa et al., 2015</xref>). To gain mechanistic insight into Dnmt3a-mediated IR at the molecular level, we performed RNA-seq in 3T3-L1 adipocytes, in both gain- and loss-of-function contexts. We have successfully used this approach to enhance our ability to identify <italic>bona fide</italic> targets (<xref ref-type="bibr" rid="bib36">Kang et al., 2012</xref>). We found that 97 genes were repressed after shRNA-mediated Dnmt3a knock-down, while only eight genes were up-regulated in the presence of excess Dnmt3a; the single gene showing concordant regulation was Dnmt3a itself (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Conversely, 290 genes were induced by Dnmt3a knock-down, and 36 genes showed diminished expression after Dnmt3a overexpression; seven genes were concordantly regulated by both manipulations (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). These data are consistent with the expectation that Dnmt3a works primarily as a repressor of gene expression. Among the concordantly-regulated negative target genes of Dnmt3a, we were immediately struck by the presence of <italic>Fgf21</italic>. FGF21 is known to facilitate glucose uptake in adipocytes (<xref ref-type="bibr" rid="bib27">Ge et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Minard et al., 2016</xref>), and is a positive target gene of PPARγ (<xref ref-type="bibr" rid="bib54">Muise et al., 2008</xref>). Furthermore, mice lacking FGF21 do not support Rosi-mediated insulin sensitization in vivo (<xref ref-type="bibr" rid="bib19">Dutchak et al., 2012</xref>). We confirmed by Q-PCR that <italic>Fgf21</italic> expression is indeed reduced in cultured adipocytes overexpressing Dnmt3a, is increased in cells expressing shDnmt3a, and most importantly, is up-regulated in the adipose tissue of <italic>Dnmt3a<sup>AdiKO</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Unlike adipose tissue levels, serum levels of Fgf21 were reduced in HFD-fed <italic>Dnmt3a<sup>AdiKO</sup></italic> mice compared to controls (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 5–</xref>). To determine whether restoration of FGF21 levels could ameliorate Dnmt3a-mediated IR, we treated 3T3-L1 adipocytes that overexpress Dnmt3a with recombinant FGF21, which restored insulin sensitivity in a dose-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.028</object-id><label>Figure 5.</label><caption><title>Fgf21 is a key target gene of Dnmt3a.</title><p>Venn diagram showing the number of positive (<bold>A</bold>) and negative (<bold>B</bold>) Dnmt3a target genes through comparative analysis of RNA-seq profiles from Dnmt3a knockdown and overexpressing adipocytes. (<bold>C</bold>) Heat map showing differentially regulated genes by Dnmt3a overexpression and knock-down. Group 1: Genes that are down-regulated by Dnmt3a overexpression; Group 2: Genes that are down-regulated by Dnmt3a overexpression and up-regulated by Dnmt3a knock-down; Group 3: Genes that are up-regulated by Dnmt3a knock-down. (<bold>D</bold>) <italic>Fgf21</italic> mRNA expression in Dnmt3a overexpressor (<italic>left</italic>) and knock-down (<italic>middle</italic>) L1 adipocytes and in fractionated adipocytes (<italic>right</italic>) from <italic>Dnmt3a<sup>AdiKO</sup></italic> and <italic>Dnmt3a<sup>f/f</sup></italic> mice on HFD (n = 5). (<bold>E</bold>) Mature 3T3-L1 adipocytes expressing GFP or Dnmt3a treated with indicated amount of recombinant Fgf21 for 48 hr (or vehicle), and tested for insulin sensitivity by <sup>3</sup>H-2-DG assay. Shown is basal and insulin-stimulated glucose uptake. (<italic>n</italic> = 6 mice, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.031</object-id><label>Figure 5—source data 1.</label><caption><title>Figure 5—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.30766.029</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Serum Fgf21 levels in <italic>Dnmt3a<sup>AdiKO</sup></italic> mice.</title><p>(<bold>A</bold>) Serum Fgf21 levels measured by ELISA in WT and KO mice on 12-wk-old chow (n = 6) or after 14 weeks of HFD (n = 7, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig5s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.030</object-id><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Figure 5—figure supplement 1—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig5-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-6"><title>Dnmt3a-mediated changes in <italic>Fgf21</italic> gene expression involve changes in DNA methylation</title><p>In general, the level of DNA methylation at gene promoters is inversely correlated with mRNA expression (<xref ref-type="bibr" rid="bib34">Jones, 2012</xref>). Given the functional significance of FGF21 in Dnmt3a-mediated IR, we further examined whether Dnmt3a directly alters methylation of the 5 kb upstream promoter regions of the <italic>Fgf21</italic> gene (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Using methylated DNA precipitation PCR (MeDIP-qPCR), we detected genomic DNA hypermethylation at <italic>Fgf21</italic> promoter regions in Dnmt3a overexpressor 3T3-L1 cells compared to controls (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Conversely, DNA hypomethylation of these same regions was seen in Dnmt3a knock-down cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). In addition to the in vitro models, we conducted MeDIP-qPCR analysis using genomic DNA from fractionated adipocytes of <italic>Dnmt3a<sup>AdiKO</sup></italic> and control animals, finding reduced DNA methylation at the <italic>Fgf21</italic> promoter in KO cells (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Consistent with DNA methylation pattern at the Fgf21 promoter region, co-transfection of Dnmt3a potently inhibited promoter activity of <italic>Fgf21</italic> (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Together, these data suggest that Dnmt3a-mediated suppression of <italic>Fgf21</italic> involves changes in DNA methylation profile at key promoter regions.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.032</object-id><label>Figure 6.</label><caption><title>Dnmt3a-mediated methylation of the <italic>Fgf21</italic> gene promoter.</title><p>(<bold>A</bold>) Schematic showing the tested regions for MeDIP-qPCR at the <italic>Fgf21</italic> locus. Target regions were chosen using MethFinder (<ext-link ext-link-type="uri" xlink:href="http://www.urogene.org/methprimer">http://www.urogene.org/methprimer</ext-link>) on regions proximal (5 kb) and distal (50 kb) to the <italic>Fgf21</italic> transcription start site. (<bold>B</bold>) MeDIP-qPCR was performed using genomic DNA extracted from 3T3-L1 adipocytes transduced with GFP vs. Dnmt3a or shScr vs. shDnmt3a. Shown is relative fold enrichment of 5mC of Dnmt3a overexpressor and KD cells over control cells. (<bold>C</bold>) MeDIP-qPCR was performed using genomic DNA from Dnmt3a KO and Flox mice on HFD. Shown is relative fold enrichment of 5mC of KO over WT samples. (<bold>D</bold>) Fgf21-promoter reporter (1497/+5) assay performed by co-transfection of the indicated amounts of Dnmt3a expression vector. (<italic>n</italic> = 3 mice, p&lt;0.05, Student’s <italic>t</italic>-test, mean ±s.e.m.).</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.30766.033</object-id><label>Figure 6—source data 1.</label><caption><title>Figure 6—source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig6-v2"/></fig></sec><sec id="s2-7"><title>DNA methylation of <italic>FGF21</italic> is increased in human adipose tissue of subjects with type 2 diabetes</title><p>To translate some of our findings to humans, we investigated DNA methylation and gene expression of <italic>FGF21</italic> in human adipose tissue collected from diabetic vs. non-diabetic human subjects. In line with our mouse data, we found hypermethylation of four CpG sites annotated to <italic>FGF21</italic> in adipose tissue of subjects with type 2 diabetes compared with non-diabetic controls (<xref ref-type="fig" rid="fig7">Figure 7A</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Further, we found a negative correlation between DNA methylation and mRNA expression of <italic>FGF21</italic> in human adipose tissue (<xref ref-type="fig" rid="fig7">Figure 7B–E</xref>). Together, these data support a role for increased DNA methylation of <italic>FGF21</italic> in the regulation of adipose <italic>FGF21</italic> expression in association with metabolic disease.</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.30766.034</object-id><label>Figure 7.</label><caption><title><italic>FGF21</italic> DNA methylation in adipose tissue from subjects with T2D compared with controls.</title><p>(<bold>A</bold>) Four CpG sites annotated to <italic>FGF21</italic> with significant difference in adipose tissue DNA methylation between subjects with type 2 diabetes and controls. (p&lt;0.01, paired Wilcoxon statistics, mean ±s.d.). (<bold>B–D</bold>) Correlations between DNA methylation and mRNA expression for CpG sites significantly associated with T2D in human adipose tissue. (r = Pearson correlation coefficient.).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-30766-fig7-v2"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>While genetics plays an important role in obesity and T2D, genetic differences cannot fully explain many features of these conditions, such as discordance in monozygotic twins, and the close relationship with lifestyle factors (<xref ref-type="bibr" rid="bib50">McCarthy, 2010</xref>; <xref ref-type="bibr" rid="bib53">Morris et al., 2012</xref>; <xref ref-type="bibr" rid="bib80">Voight et al., 2010</xref>; <xref ref-type="bibr" rid="bib88">Zeggini et al., 2008</xref>). Of note, the vast majority of GWAS-proven allelic variants associated with T2D correspond much better to altered insulin secretion and islet function rather than to IR per se (<xref ref-type="bibr" rid="bib80">Voight et al., 2010</xref>). Hence, forms of non-genetic variation, such as epigenetic alterations, must also be considered. This notion has been borne out by a recent epigenome-wide association study (EWAS) linking alterations in DNA methylation to whole-body insulin sensitivity (<xref ref-type="bibr" rid="bib91">Zhao et al., 2012</xref>). Importantly, even genetic variants may cause disease in a DNA methylation-dependent manner, as has recently been shown for T2D and obesity (<xref ref-type="bibr" rid="bib16">Dayeh et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Elliott et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Nilsson et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Olsson et al., 2014</xref>; <xref ref-type="bibr" rid="bib82">Volkov et al., 2016</xref>). We have also shown that adipose tissue from patients with T2D exhibit numerous methylation and expression differences relative to unrelated healthy controls, with many of the same changes also seen in twin pairs discordant for T2D (<xref ref-type="bibr" rid="bib58">Nilsson et al., 2014</xref>). In this study, we identified increased expression of an enzymatic effector of DNA methylation, Dnmt3a, as a key epigenetic driver of IR in vitro and in vivo.</p><p>DNA methylation, like other forms of epigenomic modification, has been an attractive therapeutic target because of their plasticity and because they offer an opportunity to reprogram cells into a more healthy state. For example, administration of pan-inhibitors of histone deacetylase exerts beneficial metabolic effects in both mice and humans, such as increased energy expenditure, insulin sensitivity and secretion (<xref ref-type="bibr" rid="bib14">Christensen et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Daneshpajooh et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Sharma and Taliyan, 2016</xref>; <xref ref-type="bibr" rid="bib87">Ye, 2013</xref>). DNA methyltransferase inhibitors have also been shown to have an insulin-sensitizing effect in vivo and in vitro (<xref ref-type="bibr" rid="bib41">Kim et al., 2015</xref>). In line with pharmacological studies, mutant mouse models carrying loss-of function histone modifiers (e.g. <italic>Mll2, Ehmt1, Jmhd2a Lsd1</italic>) were shown to have profound impact on whole body metabolism (<xref ref-type="bibr" rid="bib43">Lee et al., 2006</xref>; <xref ref-type="bibr" rid="bib61">Ohno et al., 2013</xref>; <xref ref-type="bibr" rid="bib69">Sambeat et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Tateishi et al., 2009</xref>; <xref ref-type="bibr" rid="bib89">Zeng et al., 2016</xref>). It should be noted that metabolic consequences in mouse models carrying mutations of histone modifiers appear to be mainly attributable to changes in body weight. Unlike these examples, adipose-specific Dnmt3a KO mice are relatively unique in that they display improved insulin sensitivity without a change in adiposity or body weight. Similarly, the effect on insulin action is not dependent on increased beige or brown adipocytes, or on reducing intra-adipose inflammation.</p><p>Our in vitro study indicates that overexpression of Dnmt3a is sufficient to induce cell autonomous IR, however, it does not seem to be the case in vivo. Kamei et al showed that transgenic expression of Dnmt3a per se was not sufficient to render whole body IR and glucose intolerance (<xref ref-type="bibr" rid="bib35">Kamei et al., 2010</xref>) on chow, HFD, or high methyl diet with chow diet. Authors observed only a mild increase in the gene expression of proinflammatory cytokines (i.e. <italic>Mcp1</italic> and <italic>Tnfa</italic>) when animals were put on HFD. It should be noted that the major caveat of this study is the use of aP2 promoter to drive the transgene expression (<xref ref-type="bibr" rid="bib33">Jeffery et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Kang et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Lee et al., 2013</xref>); Potentially, non-adipose expression and earlier expression during development might have a compounding factor in this study. Despite these notions, it will be highly interesting to address how the combination of high methyl donor diet and HFD would affect the metabolic profile of these transgenic animals compared to controls.</p><p>Our unbiased gene expression profiling studies led us to identify <italic>Fgf21</italic> as a key target gene in adipocytes, and the data from diabetic humans suggests that this could be a conserved mechanism of IR in both mice and humans. Fgf21 is better known as a hepatokine, and the liver is the main source of circulating Fgf21 (<xref ref-type="bibr" rid="bib49">Markan et al., 2014</xref>) Adipose Fgf21 probably does not circulate, but rather acts in an autocrine/paracrine manner (<xref ref-type="bibr" rid="bib19">Dutchak et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Markan et al., 2014</xref>). In fact, levels of Fgf21 in serum were moderately reduced in Dnmt3a KO animals compared to controls, in contrast to significantly elevated adipose tissue levels. Studies have shown a positive correlation between insulin and circulating Fgf21 levels (<xref ref-type="bibr" rid="bib12">Chavez et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2008</xref>; <xref ref-type="bibr" rid="bib90">Zhang et al., 2008</xref>), suggesting that insulin may be a key determinant of Fgf21 in serum. Thus, it is possible that the reduced insulin levels in Dnmt3a KO mice on HFD may have led to reduction of Fgf21 production in liver. This notion is in line with the finding that Fgf21 serum levels are often elevated in obesity-associated IR (<xref ref-type="bibr" rid="bib25">Fisher and Maratos-Flier, 2016</xref>; <xref ref-type="bibr" rid="bib52">Morrice et al., 2017</xref>), possibly reflecting resistance to Fgf21 (<xref ref-type="bibr" rid="bib24">Fisher et al., 2010</xref>).</p><p>We propose that the local activity of Fgf21 within the fat pad is important for the improved insulin sensitivity in the knock-out mice, although formal proof of this idea would require generating adipose tissue-specific Dnmt3a and Fgf21 double knockout mice. In line with this view, there are previous studies indicating that adipose Fgf21 is insulin-sensitizing. For example, three independent studies demonstrated that mutant mice devoid of Fgf21 signaling in adipose tissue secondary to ablation of FGFR1 or bKlotho, were refractory to the insulin-sensitizing effect of Fgf21 administration (<xref ref-type="bibr" rid="bib1">Adams et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">BonDurant et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Ding et al., 2012</xref>). Some of these studies (<xref ref-type="bibr" rid="bib1">Adams et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Ding et al., 2012</xref>) suggested that adiponectin is an essential mediator of Fgf21 metabolic action; the other study (<xref ref-type="bibr" rid="bib7">BonDurant et al., 2017</xref>) suggested that adiponectin is dispensable. In our studies, albeit it did not reach statistical significance, there was a trend toward increased mRNA expression of <italic>Adipoq</italic> in both L1 and primary Dnmt3a KO adipocytes (not shown).</p><p>Control of Fgf21 expression appears to be highly tissue-specific. For example, PPARγ is an important driver of Fgf21 in adipose tissue, while PPARα serves that role in liver (<xref ref-type="bibr" rid="bib19">Dutchak et al., 2012</xref>). Other studies have also demonstrated that Fgf21 is positively regulated by PPARγ in fat (<xref ref-type="bibr" rid="bib54">Muise et al., 2008</xref>; <xref ref-type="bibr" rid="bib84">Wang et al., 2008</xref>). In addition to focused studies on <italic>Fgf21</italic> promoter regions, global DNA methylation profiling will be necessary to identify differentially methylated regions in the setting of Dnmt3a gain- and loss-of function.</p><p>A recent study demonstrated that Dnmt1 may contribute to obesity-associated inflammation and insulin resistance by promoting hypermethylation at the <italic>Adipoq</italic> locus (<xref ref-type="bibr" rid="bib41">Kim et al., 2015</xref>). Concordant with this study, we also see elevated Dnmt1 levels in the adipose tissue of obese animals. However, knockdown of Dnmt1 did not rescue insulin sensitivity in the setting of Dex or TNF, and overexpression of Dnmt1 did not reduce insulin-stimulated glucose uptake in cultured adipocytes. Based on those criteria, we chose to focus on Dnmt3a, and showed that adipose-specific deletion of this gene promoted insulin sensitivity even in weight-matched obese animals. Of note, we did not identify <italic>Adipoq</italic> as a regulated target after either deletion or overexpression of Dnmt3a.</p><p>Despite some effort, we have not yet identified the mechanism by which Dnmt3a expression is increased in obesity. We found that Dnmt3a is not induced by lipids (e.g. palmitate), pro-inflammatory signals (e.g. IL-6, LPS), high doses of insulin, or high glucose in cultured adipocytes (not shown). In our study, in vivo administration of thiazolidinediones normalized the expression of Dnmt3a in <italic>ob/ob</italic> mice but not in lean control animals. The mechanism by which PPARγ represses gene expression is not entirely clear. Trans-repression through binding of inflammatory transcription factors like NF-κB and AP-1 has been proposed as a general mechanism for this type of effect (<xref ref-type="bibr" rid="bib28">Glass and Saijo, 2010</xref>) although we note that there are PPARγ binding sites near the <italic>Dnmt3a</italic> TSS (not shown). It is thus unclear if direct or indirect (i.e. trans-repression) mechanisms account for the actions of rosiglitazone on <italic>Dnmt3a</italic> expression in obesity.</p><p>In summary, we have identified a novel role for Dnmt3a as an epigenetic mediator of adipose IR in vitro and in vivo. Future studies will be required to fully elucidate the full range of its target genomic regions and metabolic effects.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>3T3-L1 preadipocytes were obtained from ATCC and maintained and differentiated as described (<xref ref-type="bibr" rid="bib36">Kang et al., 2012</xref>). These cells were authenticated by the ability to differentiate and confirmed to be mycoplasma negative. To generate lentivirus particles, lentiviral constructs were co-transfected with pM2DG- and psPAX-expressing plasmids into 293T cells. After 48 hr, virus-containing supernatant was collected, filtered through 0.45 μm filters, and added to mature 3T3-L1 adipocytes for 24 hr along with 8 μg/ml Polybrene. Transduction efficiency was determined by comparison with cells transduced in parallel with a GFP-expressing lentivirus. For the ex vivo system, subcutaneous adipose tissue from wild-type C57Bl/6 mice was fractionated with digestion buffer (10 mg/ml collagenase D, 2.4 units of dispase II, 10 mM ​CaCl<sub>2</sub> in PBS). Cells from the stromal-vascular fraction (SVF) were plated in culture and differentiated as described previously (<xref ref-type="bibr" rid="bib64">Qureshi et al., 2014</xref>). ​To differentiate hASCs, Rosi (5 <underline>µ</underline>M) was added in addition to IBMX (0.5 mM), insulin (5 <underline>µ</underline>g/ml), and dexamethasone (1 <underline>µ</underline>M), from day 0–2.</p></sec><sec id="s4-2"><title><sup>3</sup>H-2-DG assay</title><p>Mature 3T3-L1 adipocytes were incubated in serum-free DMEM for 4–6 hr. Cells were then washed three times with KRH buffer (12 mM HEPES, pH 7.4, 121 mM NaCl, 5 mM KCl, 0.33 mM CaCl<sub>2</sub>, and 1.2 mM MgSO<sub>4</sub>) and incubated for 20 min in KRH buffer in the absence or presence of 50 nM insulin. Cells were treated with 2-deoxy-d-[2,6-<sup>3</sup>H]-glucose (0.33 μCi/ml) for another 10 min. Glucose uptake was stopped quickly by three rapid washes with KRH buffer containing 200 mM glucose and 10 μM cytochalasin B on ice. Cells were solubilized in 0.1% SDS for 30 min, and radioactivity was measured by liquid scintillation counting.</p></sec><sec id="s4-3"><title>Reagents</title><p>2-Deoxy-d-[2,6-<sup>3</sup>H]-glucose was purchased from PerkinElmer NEN radiochemicals. Insulin, dexamethasone, isobutylmethylxanthine (IBMX), cytochalasin B, glucose, 2-deoxyglucose, 5-Aza, ECCG, and TF-3 were purchased from Sigma-Aldrich. Recombinant TNF-α and Fgf21 were purchased from Millipore. RG-108 was purchased from Stemgent.</p></sec><sec id="s4-4"><title>Antibodies</title><p>Antibodies were purchased from Cell Signaling (Dnmt3a, 3598S; Akt, 9272; pAkt [S473], 3787; IRS-1, 2382), and from Thermo Fisher (β-actin, MA5-14739, pIRS1[pY612], 44–816G).</p></sec><sec id="s4-5"><title>Animals</title><p>For ​rosiglitazone studies, female mice <italic>ob/ob</italic> and <italic>ob/</italic>+were treated starting at 8 weeks of age with ​rosiglitazone by gavage (10 mg/kg body weight) in 0.5% carboxymethylcellulose versus 0.5% carboxymethylcellulose vehicle control daily for 6 weeks. For chow and high-fat feeding studies, male C57Bl/6J mice were put on diet beginning at 8 weeks of age and continued for three months (<italic>n</italic> = 8 per dietary condition). Samples were collected from the perigonadal fat pad.</p><p>For histology, adipose tissues were fixed with neutral-buffered formalin and embedded in paraffin and sections were stained with H&amp;E.</p><p>For in vivo insulin signaling assay, after overnight fast, insulin (10 U/kg, 5 min) or saline IP were given to WT and KO mice on HFD. After 10 min various tissues were harvested and stored at –80°C until use. Tissue samples were homogenized in cell signaling lysis buffer containing protease inhibitors (Roche) and phosphatase inhibitors (Sigma-Aldrich) and subjected to western blotting. All animal work was approved by the BIDMC IACUC and/or the UC Berkeley ACUC.</p></sec><sec id="s4-6"><title>RNA extraction and quantitative PCR</title><p>Total RNA was extracted from cells or tissues using TRIzol reagent according to the manufacturer’s instructions. cDNA was reverse-transcribed from 1 μg of RNA using the RETROscript first strand synthesis kit (Ambion). Quantitative PCR (qPCR) was performed with SYBR Green qPCR Master Mix (Applied Biosystems) using a 7900HT Fast Real-Time PCR System (Applied Biosystems) and CFX96 Touch (Bio Rad). Primer sequences are listed in <bold><xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</bold> The relative amount of mRNA normalized to ​cyclophilin B was calculated using the delta–delta method (<xref ref-type="bibr" rid="bib48">Livak and Schmittgen, 2001</xref>).</p></sec><sec id="s4-7"><title>Plasmids</title><p>Hairpins against Dnmt1, Dnmt3a, and Dnmt3b were purchased from Sigma. Lentiviral overexpression vectors for Dnmt1, 3a, and 3b were subcloned into pCDH using various multicloning sites (XbaI/NotI for ​Dnmt1, EcoRI/NotI for Dnmt1, Dnmt3a, Dnmt3a-CM) and NotI sites and hairpins targeting <italic>​Dnmts</italic> were subcloned at AgeI/EcoRI or purchased from Open Biosystems. Hairpin sequences are shown in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. Fgf21-luc (1497/+5) was generously provided by Dr. Steven Kliewer (UT Southwestern).</p></sec><sec id="s4-8"><title>MeDIP-qPCR</title><p>Genomic DNA was sheared by sonication to an average of 200–800 bp size. Two microgram of denatured DNA was incubated with 2 μg of anti-5-methylcytidine antibody (Epigentek) in IP buffer (10 mM Na-Phosphate pH 7.0, 0.14 M NaCl, 0.05% Triton X-100) for 2 hr at 4°C. Antibody-bound DNA was collected with 20 μl of Dynabeads anti-mouse IgG (Invitrogen Dynal, Oslo, Norway) for 1 hr at 4°C on a rotating wheel and successively washed five times with washing buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), and twice with TE (10 mM Tris·Cl, 1 mM EDTA pH 8.0). DNA was recovered in digestion buffer 125 μl buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS, 35 μg proteinase K) and incubated for 3 hr at 65°C. Recovered DNA was used for qPCR analysis. Primers for MeDIP-qPCR studies are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. All data are normalized to input.</p></sec><sec id="s4-9"><title>RNA-seq studies</title><p>mRNA was purified from 100 ng of total RNA using the Ribo-Zero Magnetic Gold Kit (catalog MRZG126, Illumina). Libraries were prepared using the TruSeq RNA Library Preparation Kit v2 (catalog RS-122–2001, Illumina) according to the manufacturer’s protocol starting with the EPF step. Sequencing was performed on the Illumina HiSeq2500. RNA-Seq data are aligned using TopHat2 (<xref ref-type="bibr" rid="bib40">Kim et al., 2013</xref>). Reads are assigned to transcripts using featureCounts and an mm9 genome modified to minimize overlapping transcripts (<xref ref-type="bibr" rid="bib47">Liao et al., 2014</xref>). Differential expression analysis of the data is performed using <italic>EdgeR</italic> (<xref ref-type="bibr" rid="bib67">Robinson et al., 2010</xref>).</p></sec><sec id="s4-10"><title>DNA methylation and mRNA expression in human adipose tissue</title><p>DNA methylation was analyzed in adipose tissue from 28 subjects with type 2 diabetes and 28 controls as well as in adipose tissue of 14 monozygotic twin pairs (n = 28) using Infinium HumanMethylation450 BeadChips (Illumina) according to our previous study where we also present the characteristics of these subjects (<xref ref-type="bibr" rid="bib58">Nilsson et al., 2014</xref>). Their characteristics are presented in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. mRNA was analyzed in adipose tissue from the 12 monozygotic twin pairs (n = 24) using GeneChip Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA) according to the manufacturer’s recommendations. In the present study, we studied mRNA expression and DNA methylation of CpG sites annotated to <italic>FGF21</italic>. DNA and RNA were extracted from human adipose tissue as presented (<xref ref-type="bibr" rid="bib58">Nilsson et al., 2014</xref>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>Work was funded by NIH R01 102173, 102170, and 085171 to EDR and AHA Award #15SDG25240017 to SK. We thank Jeff Leung for technical assistance and the Rosen and the Kang Lab members for helpful conversations. We are also grateful to Drs. Hei Sook Sul, Jen-Chywan Wally Wang, and Andreas Stahl for constructive comments.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Carried out most of biological experiments and assisted with preparing the manuscript</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Collected human adipose tissue and analyzed DNA methylation and gene expression with human sample</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Generated RNA-Seq library</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Generated and analyzed RNA-Seq data</p></fn><fn fn-type="con" id="con5"><p>Resources, Helped with metabolic characterization of knock-out mouse models</p></fn><fn fn-type="con" id="con6"><p>Investigation, Carried out insulin signaling assay</p></fn><fn fn-type="con" id="con7"><p>Investigation, Carried out gene expression analysis of several biological experiments</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Helped with RNA-Seq data analysis, Generated figures, Submitted GEO data</p></fn><fn fn-type="con" id="con9"><p>Investigation, Collected human adipose tissue and analyzed DNA methylation and gene expression with human sample</p></fn><fn fn-type="con" id="con10"><p>Resources, Investigation, Collected human adipose tissue and analyzed DNA methylation and gene expression data, Supervised overall human data set</p></fn><fn fn-type="con" id="con11"><p>Supervision, Funding acquisition, Writing—original draft, Writing—review and editing, Supervised experiments and edited the manuscript and revision for the revision</p></fn><fn fn-type="con" id="con12"><p>Supervision, Investigation, Writing—original draft, Writing—review and editing, Designed most of biological experiments, Supervised experiments, Wrote draft and revision for the revision</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal work was approved by the BIDMC IACUC (056-2017) and/or the UC Berkeley ACUC (AUP-2015-08-7887).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.30766.035</object-id><label>Supplementary file 1.</label><caption><title>Genes that are up-regulated (UP) and down-regulated (DOWN) Dnmt3a vs.</title><p>GFP and shDnmt3a/shScr.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.30766.036</object-id><label>Supplementary file 2.</label><caption><title>DNA methylation of four CpG sites annotated to Fgf21 showing differential DNA methylation in adipose tissue of a case control study for type 2 diabetes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-30766-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.30766.037</object-id><label>Supplementary file 3.</label><caption><title>Oligonucleotide sequences used in this manuscript.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-30766-supp3-v2.docx"/></supplementary-material><supplementary-material id="supp4"><object-id pub-id-type="doi">10.7554/eLife.30766.038</object-id><label>Supplementary file 4.</label><caption><title>Clinical characteristics of study subjects included in the discordant twin cohort and the case control cohort.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-30766-supp4-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.30766.039</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-30766-transrepform-v2.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>AC</given-names></name><name><surname>Coskun</surname> <given-names>T</given-names></name><name><surname>Cheng</surname> <given-names>CC</given-names></name><name><surname>O Farrell</surname> <given-names>LS</given-names></name><name><surname>Dubois</surname> <given-names>SL</given-names></name><name><surname>Kharitonenkov</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones</article-title><source>Molecular Metabolism</source><volume>2</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2013.05.005</pub-id><pub-id pub-id-type="pmid">24049735</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachman</surname> <given-names>KE</given-names></name><name><surname>Rountree</surname> <given-names>MR</given-names></name><name><surname>Baylin</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>32282</fpage><lpage>32287</lpage><pub-id pub-id-type="doi">10.1074/jbc.M104661200</pub-id><pub-id pub-id-type="pmid">11427539</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barres</surname> <given-names>R</given-names></name><name><surname>Kirchner</surname> <given-names>H</given-names></name><name><surname>Rasmussen</surname> <given-names>M</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Kantor</surname> <given-names>FR</given-names></name><name><surname>Krook</surname> <given-names>A</given-names></name><name><surname>Näslund</surname> <given-names>E</given-names></name><name><surname>Zierath</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Weight loss after gastric bypass surgery in human obesity remodels promoter methylation</article-title><source>Cell Reports</source><volume>3</volume><fpage>1020</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.03.018</pub-id><pub-id pub-id-type="pmid">23583180</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrès</surname> <given-names>R</given-names></name><name><surname>Osler</surname> <given-names>ME</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Rune</surname> <given-names>A</given-names></name><name><surname>Fritz</surname> <given-names>T</given-names></name><name><surname>Caidahl</surname> <given-names>K</given-names></name><name><surname>Krook</surname> <given-names>A</given-names></name><name><surname>Zierath</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density</article-title><source>Cell Metabolism</source><volume>10</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.07.011</pub-id><pub-id pub-id-type="pmid">19723495</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrès</surname> <given-names>R</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Egan</surname> <given-names>B</given-names></name><name><surname>Treebak</surname> <given-names>JT</given-names></name><name><surname>Rasmussen</surname> <given-names>M</given-names></name><name><surname>Fritz</surname> <given-names>T</given-names></name><name><surname>Caidahl</surname> <given-names>K</given-names></name><name><surname>Krook</surname> <given-names>A</given-names></name><name><surname>O'Gorman</surname> <given-names>DJ</given-names></name><name><surname>Zierath</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Acute exercise remodels promoter methylation in human skeletal muscle</article-title><source>Cell Metabolism</source><volume>15</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.01.001</pub-id><pub-id pub-id-type="pmid">22405075</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Isoda</surname> <given-names>T</given-names></name><name><surname>Murre</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>New roles for DNA cytosine modification, eRNA, anchors, and superanchors in developing B cell progenitors</article-title><source>PNAS</source><volume>112</volume><fpage>12776</fpage><lpage>12781</lpage><pub-id pub-id-type="doi">10.1073/pnas.1512995112</pub-id><pub-id pub-id-type="pmid">26417104</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BonDurant</surname> <given-names>LD</given-names></name><name><surname>Ameka</surname> <given-names>M</given-names></name><name><surname>Naber</surname> <given-names>MC</given-names></name><name><surname>Markan</surname> <given-names>KR</given-names></name><name><surname>Idiga</surname> <given-names>SO</given-names></name><name><surname>Acevedo</surname> <given-names>MR</given-names></name><name><surname>Walsh</surname> <given-names>SA</given-names></name><name><surname>Ornitz</surname> <given-names>DM</given-names></name><name><surname>Potthoff</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FGF21 regulates metabolism through adipose-dependent and -independent mechanisms</article-title><source>Cell Metabolism</source><volume>25</volume><fpage>935</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.03.005</pub-id><pub-id pub-id-type="pmid">28380381</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boucher</surname> <given-names>J</given-names></name><name><surname>Kleinridders</surname> <given-names>A</given-names></name><name><surname>Kahn</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Insulin receptor signaling in normal and insulin-resistant states</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>6</volume><elocation-id>a009191</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a009191</pub-id><pub-id pub-id-type="pmid">24384568</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brueckner</surname> <given-names>B</given-names></name><name><surname>Garcia Boy</surname> <given-names>R</given-names></name><name><surname>Siedlecki</surname> <given-names>P</given-names></name><name><surname>Musch</surname> <given-names>T</given-names></name><name><surname>Kliem</surname> <given-names>HC</given-names></name><name><surname>Zielenkiewicz</surname> <given-names>P</given-names></name><name><surname>Suhai</surname> <given-names>S</given-names></name><name><surname>Wiessler</surname> <given-names>M</given-names></name><name><surname>Lyko</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases</article-title><source>Cancer Research</source><volume>65</volume><fpage>6305</fpage><lpage>6311</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2957</pub-id><pub-id pub-id-type="pmid">16024632</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carone</surname> <given-names>BR</given-names></name><name><surname>Fauquier</surname> <given-names>L</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Shea</surname> <given-names>JM</given-names></name><name><surname>Hart</surname> <given-names>CE</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Bock</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Zamore</surname> <given-names>PD</given-names></name><name><surname>Meissner</surname> <given-names>A</given-names></name><name><surname>Weng</surname> <given-names>Z</given-names></name><name><surname>Hofmann</surname> <given-names>HA</given-names></name><name><surname>Friedman</surname> <given-names>N</given-names></name><name><surname>Rando</surname> <given-names>OJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals</article-title><source>Cell</source><volume>143</volume><fpage>1084</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.12.008</pub-id><pub-id pub-id-type="pmid">21183072</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Challen</surname> <given-names>GA</given-names></name><name><surname>Sun</surname> <given-names>D</given-names></name><name><surname>Jeong</surname> <given-names>M</given-names></name><name><surname>Luo</surname> <given-names>M</given-names></name><name><surname>Jelinek</surname> <given-names>J</given-names></name><name><surname>Berg</surname> <given-names>JS</given-names></name><name><surname>Bock</surname> <given-names>C</given-names></name><name><surname>Vasanthakumar</surname> <given-names>A</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Xi</surname> <given-names>Y</given-names></name><name><surname>Liang</surname> <given-names>S</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Darlington</surname> <given-names>GJ</given-names></name><name><surname>Meissner</surname> <given-names>A</given-names></name><name><surname>Issa</surname> <given-names>JP</given-names></name><name><surname>Godley</surname> <given-names>LA</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Goodell</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dnmt3a is essential for hematopoietic stem cell differentiation</article-title><source>Nature Genetics</source><volume>44</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/ng.1009</pub-id><pub-id pub-id-type="pmid">22138693</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez</surname> <given-names>AO</given-names></name><name><surname>Molina-Carrion</surname> <given-names>M</given-names></name><name><surname>Abdul-Ghani</surname> <given-names>MA</given-names></name><name><surname>Folli</surname> <given-names>F</given-names></name><name><surname>Defronzo</surname> <given-names>RA</given-names></name><name><surname>Tripathy</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance</article-title><source>Diabetes Care</source><volume>32</volume><fpage>1542</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.2337/dc09-0684</pub-id><pub-id pub-id-type="pmid">19487637</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>WW</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>GY</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Qi</surname> <given-names>XY</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Boden</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus</article-title><source>Experimental and Clinical Endocrinology &amp; Diabetes</source><volume>116</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1055/s-2007-985148</pub-id><pub-id pub-id-type="pmid">17926232</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname> <given-names>DP</given-names></name><name><surname>Dahllöf</surname> <given-names>M</given-names></name><name><surname>Lundh</surname> <given-names>M</given-names></name><name><surname>Rasmussen</surname> <given-names>DN</given-names></name><name><surname>Nielsen</surname> <given-names>MD</given-names></name><name><surname>Billestrup</surname> <given-names>N</given-names></name><name><surname>Grunnet</surname> <given-names>LG</given-names></name><name><surname>Mandrup-Poulsen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus</article-title><source>Molecular Medicine</source><volume>17</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.2119/molmed.2011.00021</pub-id><pub-id pub-id-type="pmid">21274504</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneshpajooh</surname> <given-names>M</given-names></name><name><surname>Bacos</surname> <given-names>K</given-names></name><name><surname>Bysani</surname> <given-names>M</given-names></name><name><surname>Bagge</surname> <given-names>A</given-names></name><name><surname>Ottosson Laakso</surname> <given-names>E</given-names></name><name><surname>Vikman</surname> <given-names>P</given-names></name><name><surname>Eliasson</surname> <given-names>L</given-names></name><name><surname>Mulder</surname> <given-names>H</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells</article-title><source>Diabetologia</source><volume>60</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1007/s00125-016-4113-2</pub-id><pub-id pub-id-type="pmid">27796421</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayeh</surname> <given-names>TA</given-names></name><name><surname>Olsson</surname> <given-names>AH</given-names></name><name><surname>Volkov</surname> <given-names>P</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets</article-title><source>Diabetologia</source><volume>56</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1007/s00125-012-2815-7</pub-id><pub-id pub-id-type="pmid">23462794</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayeh</surname> <given-names>T</given-names></name><name><surname>Volkov</surname> <given-names>P</given-names></name><name><surname>Salö</surname> <given-names>S</given-names></name><name><surname>Hall</surname> <given-names>E</given-names></name><name><surname>Nilsson</surname> <given-names>E</given-names></name><name><surname>Olsson</surname> <given-names>AH</given-names></name><name><surname>Kirkpatrick</surname> <given-names>CL</given-names></name><name><surname>Wollheim</surname> <given-names>CB</given-names></name><name><surname>Eliasson</surname> <given-names>L</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Bacos</surname> <given-names>K</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion</article-title><source>PLoS Genetics</source><volume>10</volume><elocation-id>e1004160</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004160</pub-id><pub-id pub-id-type="pmid">24603685</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>X</given-names></name><name><surname>Boney-Montoya</surname> <given-names>J</given-names></name><name><surname>Owen</surname> <given-names>BM</given-names></name><name><surname>Bookout</surname> <given-names>AL</given-names></name><name><surname>Coate</surname> <given-names>KC</given-names></name><name><surname>Mangelsdorf</surname> <given-names>DJ</given-names></name><name><surname>Kliewer</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism</article-title><source>Cell Metabolism</source><volume>16</volume><fpage>387</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.08.002</pub-id><pub-id pub-id-type="pmid">22958921</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutchak</surname> <given-names>PA</given-names></name><name><surname>Katafuchi</surname> <given-names>T</given-names></name><name><surname>Bookout</surname> <given-names>AL</given-names></name><name><surname>Choi</surname> <given-names>JH</given-names></name><name><surname>Yu</surname> <given-names>RT</given-names></name><name><surname>Mangelsdorf</surname> <given-names>DJ</given-names></name><name><surname>Kliewer</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones</article-title><source>Cell</source><volume>148</volume><fpage>556</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.11.062</pub-id><pub-id pub-id-type="pmid">22304921</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eguchi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Kershaw</surname> <given-names>EE</given-names></name><name><surname>Chiu</surname> <given-names>PC</given-names></name><name><surname>Dushay</surname> <given-names>J</given-names></name><name><surname>Estall</surname> <given-names>JL</given-names></name><name><surname>Klein</surname> <given-names>U</given-names></name><name><surname>Maratos-Flier</surname> <given-names>E</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Transcriptional control of adipose lipid handling by IRF4</article-title><source>Cell Metabolism</source><volume>13</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.02.005</pub-id><pub-id pub-id-type="pmid">21356515</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname> <given-names>S</given-names></name><name><surname>Weiss</surname> <given-names>D</given-names></name><name><surname>Burghardt</surname> <given-names>R</given-names></name><name><surname>Infante-Duarte</surname> <given-names>C</given-names></name><name><surname>Brockhaus</surname> <given-names>S</given-names></name><name><surname>Muschler</surname> <given-names>MA</given-names></name><name><surname>Bleich</surname> <given-names>S</given-names></name><name><surname>Lehmkuhl</surname> <given-names>U</given-names></name><name><surname>Frieling</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Promoter specific DNA methylation and gene expression of POMC in acutely underweight and recovered patients with anorexia nervosa</article-title><source>Journal of Psychiatric Research</source><volume>44</volume><fpage>827</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2010.01.011</pub-id><pub-id pub-id-type="pmid">20176366</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname> <given-names>HR</given-names></name><name><surname>Shihab</surname> <given-names>HA</given-names></name><name><surname>Lockett</surname> <given-names>GA</given-names></name><name><surname>Holloway</surname> <given-names>JW</given-names></name><name><surname>McRae</surname> <given-names>AF</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Ring</surname> <given-names>SM</given-names></name><name><surname>Gaunt</surname> <given-names>TR</given-names></name><name><surname>Relton</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Role of DNA methylation in Type 2 diabetes etiology: using Genotype as a causal anchor</article-title><source>Diabetes</source><volume>66</volume><fpage>1713</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.2337/db16-0874</pub-id><pub-id pub-id-type="pmid">28246294</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname> <given-names>AP</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Fradin</surname> <given-names>D</given-names></name><name><surname>Aryee</surname> <given-names>MJ</given-names></name><name><surname>Murakami</surname> <given-names>P</given-names></name><name><surname>Aspelund</surname> <given-names>T</given-names></name><name><surname>Eiriksdottir</surname> <given-names>G</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Launer</surname> <given-names>L</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Fallin</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Personalized epigenomic signatures that are stable over time and covary with body mass index</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>49ra67</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3001262</pub-id><pub-id pub-id-type="pmid">20844285</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname> <given-names>FM</given-names></name><name><surname>Chui</surname> <given-names>PC</given-names></name><name><surname>Antonellis</surname> <given-names>PJ</given-names></name><name><surname>Bina</surname> <given-names>HA</given-names></name><name><surname>Kharitonenkov</surname> <given-names>A</given-names></name><name><surname>Flier</surname> <given-names>JS</given-names></name><name><surname>Maratos-Flier</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Obesity is a fibroblast growth factor 21 (FGF21)-resistant state</article-title><source>Diabetes</source><volume>59</volume><fpage>2781</fpage><lpage>2789</lpage><pub-id pub-id-type="doi">10.2337/db10-0193</pub-id><pub-id pub-id-type="pmid">20682689</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname> <given-names>FM</given-names></name><name><surname>Maratos-Flier</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Understanding the physiology of FGF21</article-title><source>Annual Review of Physiology</source><volume>78</volume><fpage>223</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-021115-105339</pub-id><pub-id pub-id-type="pmid">26654352</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuks</surname> <given-names>F</given-names></name><name><surname>Burgers</surname> <given-names>WA</given-names></name><name><surname>Godin</surname> <given-names>N</given-names></name><name><surname>Kasai</surname> <given-names>M</given-names></name><name><surname>Kouzarides</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>2536</fpage><lpage>2544</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.10.2536</pub-id><pub-id pub-id-type="pmid">11350943</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Hui</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Lam</surname> <given-names>KS</given-names></name><name><surname>Xu</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>34533</fpage><lpage>34541</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.248591</pub-id><pub-id pub-id-type="pmid">21846717</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname> <given-names>CK</given-names></name><name><surname>Saijo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells</article-title><source>Nature Reviews Immunology</source><volume>10</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/nri2748</pub-id><pub-id pub-id-type="pmid">20414208</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregor</surname> <given-names>MF</given-names></name><name><surname>Hotamisligil</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inflammatory mechanisms in obesity</article-title><source>Annual Review of Immunology</source><volume>29</volume><fpage>415</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101322</pub-id><pub-id pub-id-type="pmid">21219177</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijmans</surname> <given-names>BT</given-names></name><name><surname>Tobi</surname> <given-names>EW</given-names></name><name><surname>Stein</surname> <given-names>AD</given-names></name><name><surname>Putter</surname> <given-names>H</given-names></name><name><surname>Blauw</surname> <given-names>GJ</given-names></name><name><surname>Susser</surname> <given-names>ES</given-names></name><name><surname>Slagboom</surname> <given-names>PE</given-names></name><name><surname>Lumey</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Persistent epigenetic differences associated with prenatal exposure to famine in humans</article-title><source>PNAS</source><volume>105</volume><fpage>17046</fpage><lpage>17049</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806560105</pub-id><pub-id pub-id-type="pmid">18955703</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houstis</surname> <given-names>N</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Reactive oxygen species have a causal role in multiple forms of insulin resistance</article-title><source>Nature</source><volume>440</volume><fpage>944</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1038/nature04634</pub-id><pub-id pub-id-type="pmid">16612386</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b</article-title><source>Molecular and Cellular Biology</source><volume>19</volume><fpage>8211</fpage><lpage>8218</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.12.8211</pub-id><pub-id pub-id-type="pmid">10567546</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffery</surname> <given-names>E</given-names></name><name><surname>Berry</surname> <given-names>R</given-names></name><name><surname>Church</surname> <given-names>CD</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Shook</surname> <given-names>BA</given-names></name><name><surname>Horsley</surname> <given-names>V</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name><name><surname>Rodeheffer</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Characterization of Cre recombinase models for the study of adipose tissue</article-title><source>Adipocyte</source><volume>3</volume><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.4161/adip.29674</pub-id><pub-id pub-id-type="pmid">25068087</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Functions of DNA methylation: islands, start sites, gene bodies and beyond</article-title><source>Nature Reviews Genetics</source><volume>13</volume><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nrg3230</pub-id><pub-id pub-id-type="pmid">22641018</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamei</surname> <given-names>Y</given-names></name><name><surname>Suganami</surname> <given-names>T</given-names></name><name><surname>Ehara</surname> <given-names>T</given-names></name><name><surname>Kanai</surname> <given-names>S</given-names></name><name><surname>Hayashi</surname> <given-names>K</given-names></name><name><surname>Yamamoto</surname> <given-names>Y</given-names></name><name><surname>Miura</surname> <given-names>S</given-names></name><name><surname>Ezaki</surname> <given-names>O</given-names></name><name><surname>Okano</surname> <given-names>M</given-names></name><name><surname>Ogawa</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Increased expression of DNA methyltransferase 3a in obese adipose tissue: studies with transgenic mice</article-title><source>Obesity</source><volume>18</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/oby.2009.246</pub-id><pub-id pub-id-type="pmid">19680236</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Akerblad</surname> <given-names>P</given-names></name><name><surname>Kiviranta</surname> <given-names>R</given-names></name><name><surname>Gupta</surname> <given-names>RK</given-names></name><name><surname>Kajimura</surname> <given-names>S</given-names></name><name><surname>Griffin</surname> <given-names>MJ</given-names></name><name><surname>Min</surname> <given-names>J</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of early adipose commitment by Zfp521</article-title><source>PLoS Biology</source><volume>10</volume><elocation-id>e1001433</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001433</pub-id><pub-id pub-id-type="pmid">23209378</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Adipocyte-specific transgenic and knockout models</article-title><source>Methods in Enzymology</source><volume>537</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-411619-1.00001-X</pub-id><pub-id pub-id-type="pmid">24480338</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Tsai</surname> <given-names>LT</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Evertts</surname> <given-names>A</given-names></name><name><surname>Xu</surname> <given-names>S</given-names></name><name><surname>Griffin</surname> <given-names>MJ</given-names></name><name><surname>Issner</surname> <given-names>R</given-names></name><name><surname>Whitton</surname> <given-names>HJ</given-names></name><name><surname>Garcia</surname> <given-names>BA</given-names></name><name><surname>Epstein</surname> <given-names>CB</given-names></name><name><surname>Mikkelsen</surname> <given-names>TS</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/ncb3080</pub-id><pub-id pub-id-type="pmid">25503565</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Tsai</surname> <given-names>LT</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nuclear mechanisms of insulin resistance</article-title><source>Trends in Cell Biology</source><volume>26</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2016.01.002</pub-id><pub-id pub-id-type="pmid">26822036</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Kelley</surname> <given-names>R</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><source>Genome Biology</source><volume>14</volume><elocation-id>R36</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-4-r36</pub-id><pub-id pub-id-type="pmid">23618408</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>AY</given-names></name><name><surname>Park</surname> <given-names>YJ</given-names></name><name><surname>Pan</surname> <given-names>X</given-names></name><name><surname>Shin</surname> <given-names>KC</given-names></name><name><surname>Kwak</surname> <given-names>SH</given-names></name><name><surname>Bassas</surname> <given-names>AF</given-names></name><name><surname>Sallam</surname> <given-names>RM</given-names></name><name><surname>Park</surname> <given-names>KS</given-names></name><name><surname>Alfadda</surname> <given-names>AA</given-names></name><name><surname>Xu</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7585</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8585</pub-id><pub-id pub-id-type="pmid">26139044</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchner</surname> <given-names>H</given-names></name><name><surname>Sinha</surname> <given-names>I</given-names></name><name><surname>Gao</surname> <given-names>H</given-names></name><name><surname>Ruby</surname> <given-names>MA</given-names></name><name><surname>Schönke</surname> <given-names>M</given-names></name><name><surname>Lindvall</surname> <given-names>JM</given-names></name><name><surname>Barrès</surname> <given-names>R</given-names></name><name><surname>Krook</surname> <given-names>A</given-names></name><name><surname>Näslund</surname> <given-names>E</given-names></name><name><surname>Dahlman-Wright</surname> <given-names>K</given-names></name><name><surname>Zierath</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Altered DNA methylation of glycolytic and lipogenic genes in liver from obese and type 2 diabetic patients</article-title><source>Molecular Metabolism</source><volume>5</volume><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2015.12.004</pub-id><pub-id pub-id-type="pmid">26977391</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>DK</given-names></name><name><surname>Dou</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Kwak</surname> <given-names>E</given-names></name><name><surname>Kong</surname> <given-names>YY</given-names></name><name><surname>Lee</surname> <given-names>SK</given-names></name><name><surname>Roeder</surname> <given-names>RG</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Coactivator as a target gene specificity determinant for histone H3 lysine 4 methyltransferases</article-title><source>PNAS</source><volume>103</volume><fpage>15392</fpage><lpage>15397</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607313103</pub-id><pub-id pub-id-type="pmid">17021013</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KY</given-names></name><name><surname>Russell</surname> <given-names>SJ</given-names></name><name><surname>Ussar</surname> <given-names>S</given-names></name><name><surname>Boucher</surname> <given-names>J</given-names></name><name><surname>Vernochet</surname> <given-names>C</given-names></name><name><surname>Mori</surname> <given-names>MA</given-names></name><name><surname>Smyth</surname> <given-names>G</given-names></name><name><surname>Rourk</surname> <given-names>M</given-names></name><name><surname>Cederquist</surname> <given-names>C</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name><name><surname>Kahn</surname> <given-names>BB</given-names></name><name><surname>Kahn</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lessons on conditional gene targeting in mouse adipose tissue</article-title><source>Diabetes</source><volume>62</volume><fpage>864</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.2337/db12-1089</pub-id><pub-id pub-id-type="pmid">23321074</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>DV</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Yan</surname> <given-names>Q</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Goodwin</surname> <given-names>B</given-names></name><name><surname>Calle</surname> <given-names>R</given-names></name><name><surname>Brenner</surname> <given-names>MB</given-names></name><name><surname>Talukdar</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes</article-title><source>PLoS One</source><volume>9</volume><elocation-id>e111767</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111767</pub-id><pub-id pub-id-type="pmid">25365322</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Jaddoe</surname> <given-names>VW</given-names></name><name><surname>Feskens</surname> <given-names>EJ</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>G</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Exposure to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood</article-title><source>Diabetes</source><volume>59</volume><fpage>2400</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.2337/db10-0385</pub-id><pub-id pub-id-type="pmid">20622161</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname> <given-names>KJ</given-names></name><name><surname>Schmittgen</surname> <given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markan</surname> <given-names>KR</given-names></name><name><surname>Naber</surname> <given-names>MC</given-names></name><name><surname>Ameka</surname> <given-names>MK</given-names></name><name><surname>Anderegg</surname> <given-names>MD</given-names></name><name><surname>Mangelsdorf</surname> <given-names>DJ</given-names></name><name><surname>Kliewer</surname> <given-names>SA</given-names></name><name><surname>Mohammadi</surname> <given-names>M</given-names></name><name><surname>Potthoff</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding</article-title><source>Diabetes</source><volume>63</volume><fpage>4057</fpage><lpage>4063</lpage><pub-id pub-id-type="doi">10.2337/db14-0595</pub-id><pub-id pub-id-type="pmid">25008183</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genomics, type 2 diabetes, and obesity</article-title><source>New England Journal of Medicine</source><volume>363</volume><fpage>2339</fpage><lpage>2350</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0906948</pub-id><pub-id pub-id-type="pmid">21142536</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minard</surname> <given-names>AY</given-names></name><name><surname>Tan</surname> <given-names>SX</given-names></name><name><surname>Yang</surname> <given-names>P</given-names></name><name><surname>Fazakerley</surname> <given-names>DJ</given-names></name><name><surname>Domanova</surname> <given-names>W</given-names></name><name><surname>Parker</surname> <given-names>BL</given-names></name><name><surname>Humphrey</surname> <given-names>SJ</given-names></name><name><surname>Jothi</surname> <given-names>R</given-names></name><name><surname>Stöckli</surname> <given-names>J</given-names></name><name><surname>James</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes</article-title><source>Cell Reports</source><volume>17</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.086</pub-id><pub-id pub-id-type="pmid">27681418</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrice</surname> <given-names>N</given-names></name><name><surname>Mcilroy</surname> <given-names>GD</given-names></name><name><surname>Tammireddy</surname> <given-names>SR</given-names></name><name><surname>Reekie</surname> <given-names>J</given-names></name><name><surname>Shearer</surname> <given-names>KD</given-names></name><name><surname>Doherty</surname> <given-names>MK</given-names></name><name><surname>Delibegović</surname> <given-names>M</given-names></name><name><surname>Whitfield</surname> <given-names>PD</given-names></name><name><surname>Mody</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>43782</elocation-id><pub-id pub-id-type="doi">10.1038/srep43782</pub-id><pub-id pub-id-type="pmid">28256636</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Segrè</surname> <given-names>AV</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Strawbridge</surname> <given-names>RJ</given-names></name><name><surname>Khan</surname> <given-names>H</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name><name><surname>Dina</surname> <given-names>C</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Fraser</surname> <given-names>RM</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Lagou</surname> <given-names>V</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Pechlivanis</surname> <given-names>S</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Wiltshire</surname> <given-names>S</given-names></name><name><surname>Yengo</surname> <given-names>L</given-names></name><name><surname>Kinnunen</surname> <given-names>L</given-names></name><name><surname>Rossin</surname> <given-names>EJ</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Johnson</surname> <given-names>AD</given-names></name><name><surname>Dimas</surname> <given-names>AS</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Vedantam</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Fox</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>CT</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Couper</surname> <given-names>DJ</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Cornelis</surname> <given-names>MC</given-names></name><name><surname>Kraft</surname> <given-names>P</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>van Dam</surname> <given-names>RM</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Fontanillas</surname> <given-names>P</given-names></name><name><surname>Holmen</surname> <given-names>OL</given-names></name><name><surname>Hunt</surname> <given-names>SE</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Lawrence</surname> <given-names>R</given-names></name><name><surname>Meyer</surname> <given-names>J</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Platou</surname> <given-names>CG</given-names></name><name><surname>Potter</surname> <given-names>S</given-names></name><name><surname>Rehnberg</surname> <given-names>E</given-names></name><name><surname>Robertson</surname> <given-names>N</given-names></name><name><surname>Sivapalaratnam</surname> <given-names>S</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Stirrups</surname> <given-names>K</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Tikkanen</surname> <given-names>E</given-names></name><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Atalay</surname> <given-names>M</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Burtt</surname> <given-names>N</given-names></name><name><surname>Carey</surname> <given-names>J</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Crenshaw</surname> <given-names>AT</given-names></name><name><surname>Doney</surname> <given-names>AS</given-names></name><name><surname>Dorkhan</surname> <given-names>M</given-names></name><name><surname>Edkins</surname> <given-names>S</given-names></name><name><surname>Emilsson</surname> <given-names>V</given-names></name><name><surname>Eury</surname> <given-names>E</given-names></name><name><surname>Forsen</surname> <given-names>T</given-names></name><name><surname>Gertow</surname> <given-names>K</given-names></name><name><surname>Gigante</surname> <given-names>B</given-names></name><name><surname>Grant</surname> <given-names>GB</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Guiducci</surname> <given-names>C</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Hreidarsson</surname> <given-names>AB</given-names></name><name><surname>Hui</surname> <given-names>J</given-names></name><name><surname>James</surname> <given-names>A</given-names></name><name><surname>Jonsson</surname> <given-names>A</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Kravic</surname> <given-names>J</given-names></name><name><surname>Krjutškov</surname> <given-names>K</given-names></name><name><surname>Langford</surname> <given-names>C</given-names></name><name><surname>Leander</surname> <given-names>K</given-names></name><name><surname>Lindholm</surname> <given-names>E</given-names></name><name><surname>Lobbens</surname> <given-names>S</given-names></name><name><surname>Männistö</surname> <given-names>S</given-names></name><name><surname>Mirza</surname> <given-names>G</given-names></name><name><surname>Mühleisen</surname> <given-names>TW</given-names></name><name><surname>Musk</surname> <given-names>B</given-names></name><name><surname>Parkin</surname> <given-names>M</given-names></name><name><surname>Rallidis</surname> <given-names>L</given-names></name><name><surname>Saramies</surname> <given-names>J</given-names></name><name><surname>Sennblad</surname> <given-names>B</given-names></name><name><surname>Shah</surname> <given-names>S</given-names></name><name><surname>Sigurðsson</surname> <given-names>G</given-names></name><name><surname>Silveira</surname> <given-names>A</given-names></name><name><surname>Steinbach</surname> <given-names>G</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Trakalo</surname> <given-names>J</given-names></name><name><surname>Veglia</surname> <given-names>F</given-names></name><name><surname>Wennauer</surname> <given-names>R</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Zabaneh</surname> <given-names>D</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>van Duijn</surname> <given-names>C</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Sijbrands</surname> <given-names>E</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Owen</surname> <given-names>KR</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Trip</surname> <given-names>MD</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Syvänen</surname> <given-names>AC</given-names></name><name><surname>Eriksson</surname> <given-names>JG</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name><name><surname>Nöthen</surname> <given-names>MM</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Hunter</surname> <given-names>DJ</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Wilsgaard</surname> <given-names>T</given-names></name><name><surname>Beilby</surname> <given-names>J</given-names></name><name><surname>Hovingh</surname> <given-names>K</given-names></name><name><surname>Price</surname> <given-names>JF</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Rauramaa</surname> <given-names>R</given-names></name><name><surname>Lakka</surname> <given-names>TA</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Dedoussis</surname> <given-names>G</given-names></name><name><surname>Njølstad</surname> <given-names>I</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Khaw</surname> <given-names>KT</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname> <given-names>SM</given-names></name><name><surname>Saaristo</surname> <given-names>TE</given-names></name><name><surname>Korpi-Hyövälti</surname> <given-names>E</given-names></name><name><surname>Saltevo</surname> <given-names>J</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Cauchi</surname> <given-names>S</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Baldassarre</surname> <given-names>D</given-names></name><name><surname>Tremoli</surname> <given-names>E</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Erbel</surname> <given-names>R</given-names></name><name><surname>Jöckel</surname> <given-names>KH</given-names></name><name><surname>Moebus</surname> <given-names>S</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Donnelly</surname> <given-names>PJ</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Nilsson</surname> <given-names>PM</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Hu</surname> <given-names>F</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><collab>Wellcome Trust Case Control Consortium</collab><collab>Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators</collab><collab>Genetic Investigation of ANthropometric Traits (GIANT) Consortium</collab><collab>Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium</collab><collab>South Asian Type 2 Diabetes (SAT2D) Consortium</collab><collab>DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes</article-title><source>Nature Genetics</source><volume>44</volume><fpage>981</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1038/ng.2383</pub-id><pub-id pub-id-type="pmid">22885922</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muise</surname> <given-names>ES</given-names></name><name><surname>Azzolina</surname> <given-names>B</given-names></name><name><surname>Kuo</surname> <given-names>DW</given-names></name><name><surname>El-Sherbeini</surname> <given-names>M</given-names></name><name><surname>Tan</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Mu</surname> <given-names>J</given-names></name><name><surname>Thompson</surname> <given-names>JR</given-names></name><name><surname>Berger</surname> <given-names>JP</given-names></name><name><surname>Wong</surname> <given-names>KK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states</article-title><source>Molecular Pharmacology</source><volume>74</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1124/mol.108.044826</pub-id><pub-id pub-id-type="pmid">18467542</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Multhaup</surname> <given-names>ML</given-names></name><name><surname>Seldin</surname> <given-names>MM</given-names></name><name><surname>Jaffe</surname> <given-names>AE</given-names></name><name><surname>Lei</surname> <given-names>X</given-names></name><name><surname>Kirchner</surname> <given-names>H</given-names></name><name><surname>Mondal</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Rodriguez</surname> <given-names>V</given-names></name><name><surname>Drong</surname> <given-names>A</given-names></name><name><surname>Hussain</surname> <given-names>M</given-names></name><name><surname>Lindgren</surname> <given-names>C</given-names></name><name><surname>McCarthy</surname> <given-names>M</given-names></name><name><surname>Näslund</surname> <given-names>E</given-names></name><name><surname>Zierath</surname> <given-names>JR</given-names></name><name><surname>Wong</surname> <given-names>GW</given-names></name><name><surname>Feinberg</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>138</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.014</pub-id><pub-id pub-id-type="pmid">25565211</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname> <given-names>SF</given-names></name><name><surname>Lin</surname> <given-names>RC</given-names></name><name><surname>Laybutt</surname> <given-names>DR</given-names></name><name><surname>Barres</surname> <given-names>R</given-names></name><name><surname>Owens</surname> <given-names>JA</given-names></name><name><surname>Morris</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chronic high-fat diet in fathers programs β-cell dysfunction in female rat offspring</article-title><source>Nature</source><volume>467</volume><fpage>963</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1038/nature09491</pub-id><pub-id pub-id-type="pmid">20962845</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>S</given-names></name><name><surname>Meletis</surname> <given-names>K</given-names></name><name><surname>Fu</surname> <given-names>D</given-names></name><name><surname>Jhaveri</surname> <given-names>S</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan</article-title><source>Developmental Dynamics</source><volume>236</volume><fpage>1663</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21176</pub-id><pub-id pub-id-type="pmid">17477386</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname> <given-names>E</given-names></name><name><surname>Jansson</surname> <given-names>PA</given-names></name><name><surname>Perfilyev</surname> <given-names>A</given-names></name><name><surname>Volkov</surname> <given-names>P</given-names></name><name><surname>Pedersen</surname> <given-names>M</given-names></name><name><surname>Svensson</surname> <given-names>MK</given-names></name><name><surname>Poulsen</surname> <given-names>P</given-names></name><name><surname>Ribel-Madsen</surname> <given-names>R</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Fadista</surname> <given-names>J</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Klarlund Pedersen</surname> <given-names>B</given-names></name><name><surname>Scheele</surname> <given-names>C</given-names></name><name><surname>Vaag</surname> <given-names>A</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes</article-title><source>Diabetes</source><volume>63</volume><fpage>2962</fpage><lpage>2976</lpage><pub-id pub-id-type="doi">10.2337/db13-1459</pub-id><pub-id pub-id-type="pmid">24812430</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname> <given-names>E</given-names></name><name><surname>Matte</surname> <given-names>A</given-names></name><name><surname>Perfilyev</surname> <given-names>A</given-names></name><name><surname>de Mello</surname> <given-names>VD</given-names></name><name><surname>Käkelä</surname> <given-names>P</given-names></name><name><surname>Pihlajamäki</surname> <given-names>J</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>100</volume><fpage>E1491</fpage><lpage>E1501</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-3204</pub-id><pub-id pub-id-type="pmid">26418287</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname> <given-names>K</given-names></name><name><surname>Iwamoto</surname> <given-names>Y</given-names></name><name><surname>Kobayashi</surname> <given-names>Y</given-names></name><name><surname>Katsuoka</surname> <given-names>F</given-names></name><name><surname>Kawaguchi</surname> <given-names>S</given-names></name><name><surname>Tsujita</surname> <given-names>T</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Kato</surname> <given-names>S</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Takayanagi</surname> <given-names>H</given-names></name><name><surname>Ishii</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway</article-title><source>Nature Medicine</source><volume>21</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nm.3774</pub-id><pub-id pub-id-type="pmid">25706873</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname> <given-names>H</given-names></name><name><surname>Shinoda</surname> <given-names>K</given-names></name><name><surname>Ohyama</surname> <given-names>K</given-names></name><name><surname>Sharp</surname> <given-names>LZ</given-names></name><name><surname>Kajimura</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex</article-title><source>Nature</source><volume>504</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/nature12652</pub-id><pub-id pub-id-type="pmid">24196706</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname> <given-names>AH</given-names></name><name><surname>Volkov</surname> <given-names>P</given-names></name><name><surname>Bacos</surname> <given-names>K</given-names></name><name><surname>Dayeh</surname> <given-names>T</given-names></name><name><surname>Hall</surname> <given-names>E</given-names></name><name><surname>Nilsson</surname> <given-names>EA</given-names></name><name><surname>Ladenvall</surname> <given-names>C</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets</article-title><source>PLoS Genetics</source><volume>10</volume><elocation-id>e1004735</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004735</pub-id><pub-id pub-id-type="pmid">25375650</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname> <given-names>U</given-names></name><name><surname>Cao</surname> <given-names>Q</given-names></name><name><surname>Yilmaz</surname> <given-names>E</given-names></name><name><surname>Lee</surname> <given-names>AH</given-names></name><name><surname>Iwakoshi</surname> <given-names>NN</given-names></name><name><surname>Ozdelen</surname> <given-names>E</given-names></name><name><surname>Tuncman</surname> <given-names>G</given-names></name><name><surname>Görgün</surname> <given-names>C</given-names></name><name><surname>Glimcher</surname> <given-names>LH</given-names></name><name><surname>Hotamisligil</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes</article-title><source>Science</source><volume>306</volume><fpage>457</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1126/science.1103160</pub-id><pub-id pub-id-type="pmid">15486293</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname> <given-names>AT</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>F</given-names></name><name><surname>Thomas-Porch</surname> <given-names>C</given-names></name><name><surname>Gimble</surname> <given-names>JM</given-names></name><name><surname>Hayes</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human adipose-derived stromal/stem cell isolation, culture, and osteogenic differentiation</article-title><source>Methods in Enzymology</source><volume>538</volume><fpage>67</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-800280-3.00005-0</pub-id><pub-id pub-id-type="pmid">24529434</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajavelu</surname> <given-names>A</given-names></name><name><surname>Tulyasheva</surname> <given-names>Z</given-names></name><name><surname>Jaiswal</surname> <given-names>R</given-names></name><name><surname>Jeltsch</surname> <given-names>A</given-names></name><name><surname>Kuhnert</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The inhibition of the mammalian DNA methyltransferase 3a (Dnmt3a) by dietary black tea and coffee polyphenols</article-title><source>BMC Biochemistry</source><volume>12</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2091-12-16</pub-id><pub-id pub-id-type="pmid">21510884</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>KD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>DNA methylation and human disease</article-title><source>Nature Reviews Genetics</source><volume>6</volume><fpage>597</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1038/nrg1655</pub-id><pub-id pub-id-type="pmid">16136652</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>MD</given-names></name><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Poulsen</surname> <given-names>P</given-names></name><name><surname>Hansson</surname> <given-names>O</given-names></name><name><surname>Holmkvist</surname> <given-names>J</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Vaag</surname> <given-names>A</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle</article-title><source>Diabetologia</source><volume>51</volume><fpage>1159</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-1018-8</pub-id><pub-id pub-id-type="pmid">18488190</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambeat</surname> <given-names>A</given-names></name><name><surname>Gulyaeva</surname> <given-names>O</given-names></name><name><surname>Dempersmier</surname> <given-names>J</given-names></name><name><surname>Tharp</surname> <given-names>KM</given-names></name><name><surname>Stahl</surname> <given-names>A</given-names></name><name><surname>Paul</surname> <given-names>SM</given-names></name><name><surname>Sul</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>LSD1 Interacts with Zfp516 to Promote UCP1 Transcription and Brown Fat Program</article-title><source>Cell Reports</source><volume>15</volume><fpage>2536</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.019</pub-id><pub-id pub-id-type="pmid">27264172</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname> <given-names>VT</given-names></name><name><surname>Shulman</surname> <given-names>GI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mechanisms for insulin resistance: common threads and missing links</article-title><source>Cell</source><volume>148</volume><fpage>852</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.017</pub-id><pub-id pub-id-type="pmid">22385956</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Taliyan</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes</article-title><source>Pharmacological Research</source><volume>113</volume><fpage>320</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.09.009</pub-id><pub-id pub-id-type="pmid">27620069</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siersbæk</surname> <given-names>M</given-names></name><name><surname>Varticovski</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Baek</surname> <given-names>S</given-names></name><name><surname>Nielsen</surname> <given-names>R</given-names></name><name><surname>Mandrup</surname> <given-names>S</given-names></name><name><surname>Hager</surname> <given-names>GL</given-names></name><name><surname>Chung</surname> <given-names>JH</given-names></name><name><surname>Grøntved</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>40220</elocation-id><pub-id pub-id-type="doi">10.1038/srep40220</pub-id><pub-id pub-id-type="pmid">28071704</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soccio</surname> <given-names>RE</given-names></name><name><surname>Chen</surname> <given-names>ER</given-names></name><name><surname>Lazar</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes</article-title><source>Cell Metabolism</source><volume>20</volume><fpage>573</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.08.005</pub-id><pub-id pub-id-type="pmid">25242225</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Step</surname> <given-names>SE</given-names></name><name><surname>Lim</surname> <given-names>HW</given-names></name><name><surname>Marinis</surname> <given-names>JM</given-names></name><name><surname>Prokesch</surname> <given-names>A</given-names></name><name><surname>Steger</surname> <given-names>DJ</given-names></name><name><surname>You</surname> <given-names>SH</given-names></name><name><surname>Won</surname> <given-names>KJ</given-names></name><name><surname>Lazar</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>1018</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1101/gad.237628.114</pub-id><pub-id pub-id-type="pmid">24788520</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stresemann</surname> <given-names>C</given-names></name><name><surname>Lyko</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine</article-title><source>International Journal of Cancer</source><volume>123</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/ijc.23607</pub-id><pub-id pub-id-type="pmid">18425818</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugii</surname> <given-names>S</given-names></name><name><surname>Olson</surname> <given-names>P</given-names></name><name><surname>Sears</surname> <given-names>DD</given-names></name><name><surname>Saberi</surname> <given-names>M</given-names></name><name><surname>Atkins</surname> <given-names>AR</given-names></name><name><surname>Barish</surname> <given-names>GD</given-names></name><name><surname>Hong</surname> <given-names>SH</given-names></name><name><surname>Castro</surname> <given-names>GL</given-names></name><name><surname>Yin</surname> <given-names>YQ</given-names></name><name><surname>Nelson</surname> <given-names>MC</given-names></name><name><surname>Hsiao</surname> <given-names>G</given-names></name><name><surname>Greaves</surname> <given-names>DR</given-names></name><name><surname>Downes</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>RT</given-names></name><name><surname>Olefsky</surname> <given-names>JM</given-names></name><name><surname>Evans</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization</article-title><source>PNAS</source><volume>106</volume><fpage>22504</fpage><lpage>22509</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912487106</pub-id><pub-id pub-id-type="pmid">20018750</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>SX</given-names></name><name><surname>Fisher-Wellman</surname> <given-names>KH</given-names></name><name><surname>Fazakerley</surname> <given-names>DJ</given-names></name><name><surname>Ng</surname> <given-names>Y</given-names></name><name><surname>Pant</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Meoli</surname> <given-names>CC</given-names></name><name><surname>Coster</surname> <given-names>AC</given-names></name><name><surname>Stöckli</surname> <given-names>J</given-names></name><name><surname>James</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Selective insulin resistance in adipocytes</article-title><source>Journal of Biological Chemistry</source><volume>290</volume><fpage>11337</fpage><lpage>11348</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.623686</pub-id><pub-id pub-id-type="pmid">25720492</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tateishi</surname> <given-names>K</given-names></name><name><surname>Okada</surname> <given-names>Y</given-names></name><name><surname>Kallin</surname> <given-names>EM</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Role of Jhdm2a in regulating metabolic gene expression and obesity resistance</article-title><source>Nature</source><volume>458</volume><fpage>757</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1038/nature07777</pub-id><pub-id pub-id-type="pmid">19194461</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobi</surname> <given-names>EW</given-names></name><name><surname>Goeman</surname> <given-names>JJ</given-names></name><name><surname>Monajemi</surname> <given-names>R</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Putter</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Slieker</surname> <given-names>RC</given-names></name><name><surname>Stok</surname> <given-names>AP</given-names></name><name><surname>Thijssen</surname> <given-names>PE</given-names></name><name><surname>Müller</surname> <given-names>F</given-names></name><name><surname>van Zwet</surname> <given-names>EW</given-names></name><name><surname>Bock</surname> <given-names>C</given-names></name><name><surname>Meissner</surname> <given-names>A</given-names></name><name><surname>Lumey</surname> <given-names>LH</given-names></name><name><surname>Eline Slagboom</surname> <given-names>P</given-names></name><name><surname>Heijmans</surname> <given-names>BT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DNA methylation signatures link prenatal famine exposure to growth and metabolism</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5592</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6592</pub-id><pub-id pub-id-type="pmid">25424739</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Dina</surname> <given-names>C</given-names></name><name><surname>Welch</surname> <given-names>RP</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Huth</surname> <given-names>C</given-names></name><name><surname>Aulchenko</surname> <given-names>YS</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>McCulloch</surname> <given-names>LJ</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Amin</surname> <given-names>N</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Willer</surname> <given-names>CJ</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Hofmann</surname> <given-names>OM</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Segrè</surname> <given-names>AV</given-names></name><name><surname>van Hoek</surname> <given-names>M</given-names></name><name><surname>Navarro</surname> <given-names>P</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Bennett</surname> <given-names>AJ</given-names></name><name><surname>Blagieva</surname> <given-names>R</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Bengtsson Boström</surname> <given-names>K</given-names></name><name><surname>Bravenboer</surname> <given-names>B</given-names></name><name><surname>Bumpstead</surname> <given-names>S</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Cornelis</surname> <given-names>M</given-names></name><name><surname>Couper</surname> <given-names>DJ</given-names></name><name><surname>Crawford</surname> <given-names>G</given-names></name><name><surname>Doney</surname> <given-names>AS</given-names></name><name><surname>Elliott</surname> <given-names>KS</given-names></name><name><surname>Elliott</surname> <given-names>AL</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Fox</surname> <given-names>CS</given-names></name><name><surname>Franklin</surname> <given-names>CS</given-names></name><name><surname>Ganser</surname> <given-names>M</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Green</surname> <given-names>T</given-names></name><name><surname>Griffin</surname> <given-names>S</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Guiducci</surname> <given-names>C</given-names></name><name><surname>Hadjadj</surname> <given-names>S</given-names></name><name><surname>Hassanali</surname> <given-names>N</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Johnson</surname> <given-names>PR</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Kraft</surname> <given-names>P</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Lauritzen</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Lieverse</surname> <given-names>A</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Marre</surname> <given-names>M</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Midthjell</surname> <given-names>K</given-names></name><name><surname>Morken</surname> <given-names>MA</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Owen</surname> <given-names>KR</given-names></name><name><surname>Payne</surname> <given-names>F</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Petersen</surname> <given-names>AK</given-names></name><name><surname>Platou</surname> <given-names>C</given-names></name><name><surname>Proença</surname> <given-names>C</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Robertson</surname> <given-names>NR</given-names></name><name><surname>Rocheleau</surname> <given-names>G</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Sampson</surname> <given-names>MJ</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Shields</surname> <given-names>BM</given-names></name><name><surname>Shrader</surname> <given-names>P</given-names></name><name><surname>Sigurdsson</surname> <given-names>G</given-names></name><name><surname>Sparsø</surname> <given-names>T</given-names></name><name><surname>Strassburger</surname> <given-names>K</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Tichet</surname> <given-names>J</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>van Dam</surname> <given-names>RM</given-names></name><name><surname>van Haeften</surname> <given-names>TW</given-names></name><name><surname>van Herpt</surname> <given-names>T</given-names></name><name><surname>van Vliet-Ostaptchouk</surname> <given-names>JV</given-names></name><name><surname>Walters</surname> <given-names>GB</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Witteman</surname> <given-names>J</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Cauchi</surname> <given-names>S</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Gyllensten</surname> <given-names>U</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Hide</surname> <given-names>WA</given-names></name><name><surname>Hitman</surname> <given-names>GA</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hunter</surname> <given-names>DJ</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Sijbrands</surname> <given-names>E</given-names></name><name><surname>Stein</surname> <given-names>LD</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Uitterlinden</surname> <given-names>A</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Wichmann</surname> <given-names>HE</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><collab>MAGIC investigators</collab><collab>GIANT Consortium</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis</article-title><source>Nature Genetics</source><volume>42</volume><fpage>579</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/ng.609</pub-id><pub-id pub-id-type="pmid">20581827</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkmar</surname> <given-names>M</given-names></name><name><surname>Dedeurwaerder</surname> <given-names>S</given-names></name><name><surname>Cunha</surname> <given-names>DA</given-names></name><name><surname>Ndlovu</surname> <given-names>MN</given-names></name><name><surname>Defrance</surname> <given-names>M</given-names></name><name><surname>Deplus</surname> <given-names>R</given-names></name><name><surname>Calonne</surname> <given-names>E</given-names></name><name><surname>Volkmar</surname> <given-names>U</given-names></name><name><surname>Igoillo-Esteve</surname> <given-names>M</given-names></name><name><surname>Naamane</surname> <given-names>N</given-names></name><name><surname>Del Guerra</surname> <given-names>S</given-names></name><name><surname>Masini</surname> <given-names>M</given-names></name><name><surname>Bugliani</surname> <given-names>M</given-names></name><name><surname>Marchetti</surname> <given-names>P</given-names></name><name><surname>Cnop</surname> <given-names>M</given-names></name><name><surname>Eizirik</surname> <given-names>DL</given-names></name><name><surname>Fuks</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>1405</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.503</pub-id><pub-id pub-id-type="pmid">22293752</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkov</surname> <given-names>P</given-names></name><name><surname>Olsson</surname> <given-names>AH</given-names></name><name><surname>Gillberg</surname> <given-names>L</given-names></name><name><surname>Jørgensen</surname> <given-names>SW</given-names></name><name><surname>Brøns</surname> <given-names>C</given-names></name><name><surname>Eriksson</surname> <given-names>KF</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Jansson</surname> <given-names>PA</given-names></name><name><surname>Nilsson</surname> <given-names>E</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Vaag</surname> <given-names>A</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A genome-wide mQTL analysis in human adipose tissue identifies genetic variants associated with DNA methylation, gene expression and metabolic traits</article-title><source>PLos One</source><volume>11</volume><elocation-id>e0157776</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0157776</pub-id><pub-id pub-id-type="pmid">27322064</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkov</surname> <given-names>P</given-names></name><name><surname>Bacos</surname> <given-names>K</given-names></name><name><surname>Ofori</surname> <given-names>JK</given-names></name><name><surname>Esguerra</surname> <given-names>JL</given-names></name><name><surname>Eliasson</surname> <given-names>L</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes pathogenesis</article-title><source>Diabetes</source><volume>66</volume><fpage>1074</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.2337/db16-0996</pub-id><pub-id pub-id-type="pmid">28052964</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Qiang</surname> <given-names>L</given-names></name><name><surname>Farmer</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>188</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1128/MCB.00992-07</pub-id><pub-id pub-id-type="pmid">17954559</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>CR</given-names></name><name><surname>Wei</surname> <given-names>YP</given-names></name><name><surname>Zhao</surname> <given-names>ZA</given-names></name><name><surname>Hou</surname> <given-names>Y</given-names></name><name><surname>Schatten</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Paternally induced transgenerational inheritance of susceptibility to diabetes in mammals</article-title><source>PNAS</source><volume>111</volume><fpage>1873</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1073/pnas.1321195111</pub-id><pub-id pub-id-type="pmid">24449870</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>M</given-names></name><name><surname>Hong</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Lowdon</surname> <given-names>RF</given-names></name><name><surname>Xing</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Maire</surname> <given-names>CL</given-names></name><name><surname>Ligon</surname> <given-names>KL</given-names></name><name><surname>Gascard</surname> <given-names>P</given-names></name><name><surname>Sigaroudinia</surname> <given-names>M</given-names></name><name><surname>Tlsty</surname> <given-names>TD</given-names></name><name><surname>Kadlecek</surname> <given-names>T</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>O'Geen</surname> <given-names>H</given-names></name><name><surname>Farnham</surname> <given-names>PJ</given-names></name><name><surname>Madden</surname> <given-names>PA</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Kamoh</surname> <given-names>B</given-names></name><name><surname>Cho</surname> <given-names>S</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>Hirst</surname> <given-names>M</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Costello</surname> <given-names>JF</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape</article-title><source>Nature Genetics</source><volume>45</volume><fpage>836</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1038/ng.2649</pub-id><pub-id pub-id-type="pmid">23708189</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Improving insulin sensitivity with HDAC inhibitor</article-title><source>Diabetes</source><volume>62</volume><fpage>685</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.2337/db12-1354</pub-id><pub-id pub-id-type="pmid">23431009</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Marchini</surname> <given-names>JL</given-names></name><name><surname>Hu</surname> <given-names>T</given-names></name><name><surname>de Bakker</surname> <given-names>PI</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Andersen</surname> <given-names>G</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Boström</surname> <given-names>KB</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Borch-Johnsen</surname> <given-names>K</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Deodhar</surname> <given-names>P</given-names></name><name><surname>Ding</surname> <given-names>CJ</given-names></name><name><surname>Doney</surname> <given-names>AS</given-names></name><name><surname>Duren</surname> <given-names>WL</given-names></name><name><surname>Elliott</surname> <given-names>KS</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Freathy</surname> <given-names>RM</given-names></name><name><surname>Gianniny</surname> <given-names>L</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Guiducci</surname> <given-names>C</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Hitman</surname> <given-names>GA</given-names></name><name><surname>Hughes</surname> <given-names>TE</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Kubalanza</surname> <given-names>K</given-names></name><name><surname>Kuruvilla</surname> <given-names>FG</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Lango</surname> <given-names>H</given-names></name><name><surname>Lauritzen</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Marvelle</surname> <given-names>AF</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Midthjell</surname> <given-names>K</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Morken</surname> <given-names>MA</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Owen</surname> <given-names>KR</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Payne</surname> <given-names>F</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Pettersen</surname> <given-names>E</given-names></name><name><surname>Platou</surname> <given-names>C</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Qin</surname> <given-names>L</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Rees</surname> <given-names>M</given-names></name><name><surname>Roix</surname> <given-names>JJ</given-names></name><name><surname>Sandbaek</surname> <given-names>A</given-names></name><name><surname>Shields</surname> <given-names>B</given-names></name><name><surname>Sjögren</surname> <given-names>M</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Willer</surname> <given-names>CJ</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><collab>Wellcome Trust Case Control Consortium</collab></person-group><year iso-8601-date="2008">2008</year><article-title>Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes</article-title><source>Nature Genetics</source><volume>40</volume><fpage>638</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1038/ng.120</pub-id><pub-id pub-id-type="pmid">18372903</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>X</given-names></name><name><surname>Jedrychowski</surname> <given-names>MP</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Serag</surname> <given-names>S</given-names></name><name><surname>Lavery</surname> <given-names>GG</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name><name><surname>Spiegelman</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lysine-specific demethylase 1 promotes brown adipose tissue thermogenesis via repressing glucocorticoid activation</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>1822</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1101/gad.285312.116</pub-id><pub-id pub-id-type="pmid">27566776</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Yeung</surname> <given-names>DC</given-names></name><name><surname>Karpisek</surname> <given-names>M</given-names></name><name><surname>Stejskal</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>ZG</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Wong</surname> <given-names>RL</given-names></name><name><surname>Chow</surname> <given-names>WS</given-names></name><name><surname>Tso</surname> <given-names>AW</given-names></name><name><surname>Lam</surname> <given-names>KS</given-names></name><name><surname>Xu</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans</article-title><source>Diabetes</source><volume>57</volume><fpage>1246</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.2337/db07-1476</pub-id><pub-id pub-id-type="pmid">18252893</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Goldberg</surname> <given-names>J</given-names></name><name><surname>Bremner</surname> <given-names>JD</given-names></name><name><surname>Vaccarino</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Global DNA methylation is associated with insulin resistance: a monozygotic twin study</article-title><source>Diabetes</source><volume>61</volume><fpage>542</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.2337/db11-1048</pub-id><pub-id pub-id-type="pmid">22210312</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.30766.041</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><role>Reviewing Editor</role><aff><institution>Maine Medical Center Research Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Dnmt3a is an epigenetic mediator of adipose insulin resistance&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by Mark McCarthy (Senior Editor) and three reviewers, one of whom, Clifford J Rosen (Reviewer #1), is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal their identity: Rob Koza (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Overall there is significant enthusiasm for this manuscript, if the suggestions noted below by the reviewing editor are considered within the context of the other comments and the time frame for resubmission.</p><p>Essential revisions:</p><p>There were a couple of points that need to be addressed in the response and incorporated within the manuscript. These include three major comments:</p><p>1) A clearer rationale for studying epididymal fat as the major tissue source for the studies and elaboration about the possible beiging that could occur in the conditional deletion as a mechanism for the enhanced insulin sensitivity.</p><p>2) More elaboration about the regulation of the enzyme itself and the impact of activated PPARG on expression of Dnmt3.</p><p>3) Considerations for more in vivo proof that FGF-21 is the target repressor of Dnmt3.</p><p><italic>Reviewer #1:</italic> </p><p>Rosen and colleagues in this paper found enhanced expression of DNA methyltransferases (Dnmts) in insulin resistance. Pharmacological and genetic inhibition studies demonstrated that Dnmt3a was both necessary and sufficient to mediate insulin resistance in cultured mouse and human adipocytes. In addition, adipose-specific Dnmt3a knock-out mice were protected from diet-induced insulin resistance and glucose intolerance without accompanying changes in adiposity. Gene expression profiling studies revealed Fgf21 as a key negatively regulated Dnmt3a target gene in adipocytes with concordant changes in DNA methylation at the Fgf21 promoter region. Fgf21 rescued Dnmt3a-mediated insulin resistance in vitro, and DNA methylation at the FGF21 locus was elevated in human subjects with diabetes and correlated negatively with expression of FGF21 in human adipose tissue. Thus they concluded that adipose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.</p><p>This manuscript breaks new ground in describing an epigenetic mechanism for insulin resistance that is mediated through adipose specific FGF-21. The experiments are straightforward, the results consistent and the discussion is not over-reaching. The in vivo data are strong, and the in vitro rescue and silencing studies stand up to closer scrutiny. The human studies provide a translational perspective although somewhat limited by the confounders in T2d. The dose dependent suppression of Fgf21 luc with Dnmt3a in <xref ref-type="fig" rid="fig6">figure 6D</xref> is particularly striking. Thus overall there are considerable strengths that are both basic and translational. The concerns are relatively limited and are noted below:</p><p>1) Rosiglitazone suppressed Dnmt3a – have the authors looked at whether activated PPARG directly mediates the suppression of Dnmt3a expression, or is it one of the many downstream targets of PPARG? This is particularly relevant since the enzyme's regulation is not defined, although it increases with a HFD, albeit without a known mechanism.</p><p>2) Can the authors discuss the discrepancy in vivo between circulating FGF-21 (likely hepatic- low) and adipose FGF-21 levels (high) in the Dnmt3a KO mice?</p><p>3) The authors mention that Fgf21 null mice do not support Rosi-mediated insulin sensitivity – does crossing the Fgf21-/- with the Dnmt3 adipose specific KO restore insulin resistance in those mice fed a HFD? This certainly would provide further in vivo proof of concept that FGF-21 is the target repressor of Dnmt3a.</p><p>4) The human studies are interesting but somewhat limited by the small number of subjects and the relatively weak, albeit significant negative regressions between methylation at the Fgf21 locus and mRNA expression at CpG sites. Of concern is the lack of a description of the diabetic subjects and their controls. For example, were the T2D patients treated with oral agents and/or insulin and did concurrent treatment affect methylation expression status?</p><p>5) One of the novel aspects of these studies is the similar weight gain and fat mass change in the Drnmt3a adipose specific KO, compared to the control. Thus insulin sensitivity is maintained even in the face of greater adiposity, a key finding that needs more emphasis in the Results and Discussion.</p><p>6) The authors fail to cite the paper by Kamei et al. in Obesity 2010, which demonstrated that an aP2 transgenic Dnmt3 mouse (PMID: 19680236) exhibit similar weight gain to wt mice; but importantly those mice have increased expression of Tnfa and MCP-1 in fat from their adipose depots. Similarly in that paper Dnmt3 expression was higher in WT mice fed a HFD. There should be a citation and also discussion about that paper (limitations based on the aP2 promoter, etc.).</p><p><italic>Reviewer #2:</italic> </p><p>The manuscript entitled: 'Dnmt3a is an epigenetic mediator of adipose insulin resistance' submitted presents substantial and compelling evidence that adipose tissue Dnmt3a plays a regulatory role in insulin resistance. The PIs present a clear and logical progression of studies with knockdown and transgenic overexpression of Dnmt3a in cultured adipocytes; and, adipose tissue specific inactivation of Dnmt3a in mice. In addition, RNA-seq analyses of 3T3-L1 adipocytes with shRNA knockdown or transgenic overexpression of Dnmt3a identified Fgf21 as a Dnmt3a target gene. Analyses of the Fgf21 promoter using MeDIP-qPCR confirmed DNMT3A-mediated methylation as a mechanism for Fgf21 repression. Overall, these studies are comprehensive and very well presented; and, begin to elucidate epigenetic mechanisms that can modulate adipose tissue 'health' with respect to insulin resistance and glucose uptake.</p><p>1) What is the rationale for using the epididymal adipose tissue depot to measure HFD-mediated induction of Dnmt3a? Are there differences in HFD regulation of Dnmt3a between visceral and subcutaneous adipose tissue? Fgf21?</p><p>2) Although not as dramatic as in adipose tissue, there is a relatively robust and significant increase of Dnmt3a in skeletal muscle in mice fed a HFD (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). What is the relative expression of skeletal muscle Dnmt3a with respect to adipose tissue and liver? What are the potential implications for HFD-mediated up-regulation of skeletal muscle Dnmt3a with respect to Fgf21 expression?</p><p><italic>Reviewer #3:</italic> </p><p>The manuscript &quot;Dnmt3a is an epigenetic mediator of adipose insulin resistance&quot; by You et al. presents new data linking the DNA methyltransferase Dnmt3a to insulin resistance in adipocytes. The authors start by demonstrating increased expression of Dnmt3a in models of insulin resistance. They then do pharmacologic and genetic studies in vitro to support a role for Dnmt3a in adipocyte insulin sensitivity. They then go on to generate an adipocyte-specific Dnmt3a knockout mouse and show that it is protected from diet-induced insulin resistance. Finally, they perform mechanistic studies showing that Fgf21 is negatively regulated by Dnmt3a. This is a well-written paper, with novel data, and well-designed experiments. As such, this would be of broad interest to the readership of this journal.</p><p>If the authors are able to address the point below, the manuscript would be further strengthened:</p><p>1) In their studies here, the authors only look at Dnmt3a in gonadal white fat (eWAT). Since Dnmt3a is apparently broadly expressed, it would be interesting to know whether it is also increased in subcutaneous/beige fat and in brown fat in models of insulin resistance. Moreover, it would be relevant to know whether beige/brown fat are altered in the adipocyte-specific Dnmt3a knockout model. If for example, the mutant mouse has activated brown or beige fat, this could be an explanation for the improved glucose and insulin tolerance.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.30766.042</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>There were a couple of points that need to be addressed in the response and incorporated within the manuscript. These include three major comments:</p><p>1) A clearer rationale for studying epididymal fat as the major tissue source for the studies and elaboration about the possible beiging that could occur in the conditional deletion as a mechanism for the enhanced insulin sensitivity.</p></disp-quote><p>We now show that visceral fat depots (i.e. epididymal and mesenteric WAT) express higher levels of Dnmt3a than liver and muscle, and we also show that the levels in these depots are more responsive to the effects of HFD than inguinal WAT and interscapular BAT. Additionally, we have looked for evidence of subcutaneous browning but we see none, either by histological examination or by analysis of thermogenic gene expression.</p><disp-quote content-type="editor-comment"><p>2) More elaboration about the regulation of the enzyme itself and the impact of activated PPARG on expression of Dnmt3.</p></disp-quote><p>While we agree that this is an interesting topic, it is very difficult to tease this apart, as explained below in the response to reviewer 1. We have done several things to address this issue that have produced data but not a tremendous amount of insight. To summarize, we have tried to model the effects of obesity in cultured adipocytes using FFAs, cytokines, insulin, and glucose, none of which raise Dnmt3a levels. Treatment of cultured adipocytes with TZD does not reduce basal levels of Dnmt3a, which is consistent with the in vivo results showing that Rosi reduces Dnmt3a levels in obese but not lean mice. There are PPARγ binding sites in the murine genome that lie near the Dnmt3a TSS; whether these are functional is not easy to test given the constraints already mentioned. Complicating this further is the fact that inhibiting PPARγ in mature adipocytes leads to a general process of de-differentiation, confounding efforts to parse a specific effect on Dnmt3a expression. Very little is known about how PPARγ (or any nuclear receptor) mediates negative gene expression; we submit that detailed analysis of this is beyond the scope of this study.</p><disp-quote content-type="editor-comment"><p>3) Considerations for more in vivo proof that FGF-21 is the target repressor of Dnmt3.</p></disp-quote><p>The definitive experiment to demonstrate this in vivo would be a five allele cross of adiponectinCre, Dnmt3a Flox, and Fgf21 null mice. This experiment can’t be completed within the time frame laid out by the <italic>eLife</italic> review process, and completing it would require at least a year and half of breeding. We have therefore chosen not to pursue this as part of the current manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] 1) Rosiglitazone suppressed Dnmt3a – have the authors looked at whether activated PPARG directly mediates the suppression of Dnmt3a expression, or is it one of the many downstream targets of PPARG? This is particularly relevant since the enzyme's regulation is not defined, although it increases with a HFD, albeit without a known mechanism.</p></disp-quote><p>We appreciate (and share) the reviewer’s curiosity about this important issue, but we would argue that is a very complex subject to address. First, we know very little about negative regulation by PPARγ in general. Like many nuclear receptors that are primarily transcriptional activators, PPARγ has negative targets, including leptin and adipsin. How this occurs is unknown, although trans-repression has been proposed as a mechanism for TZD antagonism of inflammatory genes. We note that there are bona fide PPARγ sites near the <italic>Dnmt3a</italic> locus (see <xref ref-type="fig" rid="respfig1">Author response image 1</xref>), suggesting at least the possibility of direct regulation. Proving that would require CRISPRing those sites in mature adipocytes; not an easy feat. One can’t simply perform loss of function studies of PPARγ in mature adipocytes, as the cells immediately begin to dedifferentiate. This has an effect on Dnmt3a gene expression, but not the effect we are looking to study. Given these constraints, we did the following: first, we assessed whether lipids, glucose, insulin, or cytokine administration could model the effect of obesity on Dnmt3a expression in vitro. Unfortunately, they do not. Next, we tested whether rosiglitazone could repress Dnmt3a in 3T3-L1 adipocytes, and if so, whether cycloheximide would have an effect on the process. Those data are shown below. The upshot is that TZD does not repress basal Dnmt3a in adipocytes, consistent with the in vivo data shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, in that TZD rescues the increased Dnmt3a of obesity but does not cause Dnmt3a levels to go lower than those seen in lean animals. We have added discussion of these points to the manuscript. We have not included the data shown in <xref ref-type="fig" rid="respfig1">Author response image 1</xref> because we feel they don’t bring additional enlightenment to the reader, but we can do so if the reviewer and editor wish.</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>(<bold>A</bold>) Histograms of PPARγ-ChIP and histone modification fragments near the mouse <italic>Dnmt3a</italic> locus (Mikkelsen et al., 2010).</title><p>Depicted with arrow are PPARγ peaks that co-localize with H3K4me1 and/or H3K27ac enhancer peaks. (<bold>B</bold>) The effect of Rosi (1uM) on the expression of Dnmt3a in the presence/absence of cycloheximide (10ug/ml) in mature 3T3-L1 adipocytes.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-30766-resp-fig1-v2"/></fig><disp-quote content-type="editor-comment"><p>2) Can the authors discuss the discrepancy in vivo between circulating FGF-21 (likely hepatic- low) and adipose FGF-21 levels (high) in the Dnmt3a KO mice?</p></disp-quote><p>We have added additional thoughts on this topic to the Discussion.</p><disp-quote content-type="editor-comment"><p>3) The authors mention that Fgf21 null mice do not support Rosi-mediated insulin sensitivity – does crossing the Fgf21-/- with the Dnmt3 adipose specific KO restore insulin resistance in those mice fed a HFD? This certainly would provide further in vivo proof of concept that FGF-21 is the target repressor of Dnmt3a.</p></disp-quote><p>We absolutely agree that this is the definitive in vivo experiment. However, it is a five allele cross (two Dnmt3a<sup>flox</sup> alleles, two FGF21 KO alleles, and one adiponectin Cre), and we fear that the time spent on this (approximately 18 months) would unnecessarily delay this report and would dilute the impact of our findings.</p><disp-quote content-type="editor-comment"><p>4) The human studies are interesting but somewhat limited by the small number of subjects and the relatively weak, albeit significant negative regressions between methylation at the Fgf21 locus and mRNA expression at CpG sites. Of concern is the lack of a description of the diabetic subjects and their controls. For example, were the T2D patients treated with oral agents and/or insulin and did concurrent treatment affect methylation expression status?</p></disp-quote><p>Based on this valid comment, we added a table (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) describing the characteristics of the diabetics and the controls included in this study. We also added information about the treatments of the diabetics in the legend of the table. We did not find any effects of treatment (insulin and metformin) on methylation of three of the studied CpG sites or expression of <italic>Fgf21</italic> (data not shown). However, a weak effect of treatment on methylation of cg21591807 was found, but this effect did not remain significant after adjustment for multiple testing (data not shown).</p><disp-quote content-type="editor-comment"><p>5) One of the novel aspects of these studies is the similar weight gain and fat mass change in the Drnmt3a adipose specific KO, compared to the control. Thus insulin sensitivity is maintained even in the face of greater adiposity, a key finding that needs more emphasis in the Results and Discussion.</p></disp-quote><p>We appreciate reviewer’s suggestion, and we have now emphasized the importance and uniqueness of this finding in the Discussion.</p><disp-quote content-type="editor-comment"><p>6) The authors fail to cite the paper by Kamei et al. in Obesity 2010, which demonstrated that an aP2 transgenic Dnmt3 mouse (PMID: 19680236) exhibit similar weight gain to wt mice; but importantly those mice have increased expression of Tnfa and MCP-1 in fat from their adipose depots. Similarly in that paper Dnmt3 expression was higher in WT mice fed a HFD. There should be a citation and also discussion about that paper (limitations based on the aP2 promoter, etc.).</p></disp-quote><p>We thank the reviewer for bringing up this reference, which we had overlooked. We now cite it. As noted, the authors of this paper generated adipose-selective Dnmt3a-overexpressor mice, which did not show dramatic changes in whole body metabolism on chow, HFD and nor with high methyl donor diet on chow. Of note, those authors did minimal physiological characterization of these mice, restricted mainly to a single time point of body weight and serum lipids, glucose and insulin. An additional caveat, also noted by the reviewer, is the use of the aP2 (Fabp4) promoter to drive transgene expression. As described in recent papers (Jeffery et al., 2014; Kang, Kong and Rosen, 2014; Lee et al., 2013), there are significant concerns about specificity as the aP2 gene is also expressed in non-adipose tissues including macrophages. Another potential compounding factor is the ‘<italic>timing</italic>’ of aP2 expression, which is speculated to be early during adipose development. Some studies have shown that Dnmt3a affects adipogenesis (Guo, Chen, Yang, Zhu and Wu, 2016), and so, a potential developmental effect of transgene expression might have confounded interpretation of the metabolic effect in this model. Per the reviewer’s suggestion, we investigated inflammation in Dnmt3a KO mice. We observe a non-significant trend toward reduced TNF and MCP-1 expression in KO mice (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A</xref>). We also saw no obvious change in macrophage infiltration by histological examination in Dnmt3a KO mice after HFD (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B</xref>).</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[…] 1) What is the rationale for using the epididymal adipose tissue depot to measure HFD-mediated induction of Dnmt3a? Are there differences in HFD regulation of Dnmt3a between visceral and subcutaneous adipose tissue? Fgf21?</p></disp-quote><p>Epididymal adipose tissue is a large and accessible depot, and its mass correlates well with insulin resistance. We have now measured Dnmt3a expression in BAT, subcutaneous WAT, and mesenteric WAT from chow vs HFD mice (Figure 1—figure supplement A). Dnmt3a expression in all depots were significantly elevated but most prominently in visceral WAT (i.e. epididymal and mesenteric WAT).</p><disp-quote content-type="editor-comment"><p>2) Although not as dramatic as in adipose tissue, there is a relatively robust and significant increase of Dnmt3a in skeletal muscle in mice fed a HFD (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). What is the relative expression of skeletal muscle Dnmt3a with respect to adipose tissue and liver? What are the potential implications for HFD-mediated up-regulation of skeletal muscle Dnmt3a with respect to Fgf21 expression?</p></disp-quote><p>Based on the reviewer’s suggestion, we measured the relative expression of Dnmt3a between those three tissues. Protein expression of Dnmt3a is highest in epididymal fat compared to liver and muscle (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D, E</xref>). It seems possible that Dnmt3a could suppress Fgf21 levels in skeletal muscle as it does in adipose tissue. Overall, however, serum FGF21 levels rise in response to a HFD (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…] If the authors are able to address the point below, the manuscript would be further strengthened:</p><p>1) In their studies here, the authors only look at Dnmt3a in gonadal white fat (eWAT). Since Dnmt3a is apparently broadly expressed, it would be interesting to know whether it is also increased in subcutaneous/beige fat and in brown fat in models of insulin resistance. Moreover, it would be relevant to know whether beige/brown fat are altered in the adipocyte-specific Dnmt3a knockout model. If for example, the mutant mouse has activated brown or beige fat, this could be an explanation for the improved glucose and insulin tolerance.</p></disp-quote><p>This is a fair point. We now add data showing how Dnmt3a expression changes in additional depots after HFD (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>); the upshot is that there is a greater effect in visceral depots (epiWAT and mesenteric WAT) than in iWAT or BAT.</p><p>In addition, Dnmt3a KO mice do not display changes in body weight or adiposity at baseline or in response to fasting (<xref ref-type="fig" rid="fig4">Figures 4A-C</xref>), suggesting that increased thermogenesis/energy expenditure is not a likely mechanism for improved insulin sensitivity in the KO mice. However, to rule out a subtle but significant change in beige/BAT activity, we assessed the expression of major thermogenic genes in subcutaneous WAT and BAT. We confirm there is no major impact on thermogenic genes in beige and brown fat in KO animals; if anything, we note a slight <italic>reduction</italic> of <italic>Ucp1</italic> expression in subcutaneous WAT (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). We also did not observe any obvious histological changes that would suggest increased browning (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B</xref>).</p></body></sub-article></article>